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4. ABSTRACT 
 
Ovarian cancer (OC) has one of the highest death-to-incidence ratios among all 
tumor types, which points to the need for novel therapeutic and prognostic 
strategies. Indeed, the absence of relevant tumor cell lines that can recapitulate 
disease histopathology highlights an acute need for new model systems to study 
this pathology. In particular, it is still unclear whether the most common and 
aggressive form of this disease, high grade serous ovarian cancer (HGSOC), 
could arise from in the ovarian surface epithelium (OSE), as initially thought, 
or might be arising from the fimbrial epithelium. Here I addressed these issues 
in two complementary ways based on induced pluripotent stem cells: i) the 
modeling of Ovarian Cancer by somatic cell reprogramming to pluripotency of 
tumor cells; ii) the molecular characterization of HGSOC and its putative cells 
of origin. Somatic cell reprogramming, by erasing tumor-associated epigenetic 
marks while preserving the underlying genetic mutations, would allow for the 
first time the precise dissection of genetic and epigenetic contribution to this 
disease, through the differentiation of OC-iPSC into disease-relevant cell types. 
I demonstrated the feasibility of OC reprogramming through a non-integrative 
platform, showing that OC-derived iPSC are closely similar to human ESC, 
and proving their tumoral origin by whole exome sequencing. Moreover, I 
showed that independent iPSC clones derived from the same tumor upon 
trilineage differentiation in vivo show differential tumorigenic potential. For a 
more precise dissection of this phenotype, I set up a differentiation protocol 
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that allows differentiation of pluripotent cells into mesodermal progenitors, that 
are precursors of both fimbria and OSE. To isolate a pure population of these 
cells, I resorted to CRISPR/Cas9 to integrate a selection cassette in the MIXL1 
locus. By this approach, I was able to show correct gene targeting at the 
intended site, allowing also for selection of mesodermal progenitors upon 
differentiation of normal iPSC. The same approach translated to OC-derived 
iPSC would allow to study the effects of genetic mutations deprived of tumor-
associated epigenetic marks during differentiation, both at the stage of 
mesodermal progenitors and in cells directed towards the female reproductive 
epithelium in vivo. The second approach relies on the identification of specific 
molecular features of fimbria and ovarian surface epithelium, the two putative 
cells of origin of HGSOC. On this side, I offer a first glimpse on molecular 
features of HGSOC cancer and normal gynecological tissues. I could show that 
specific DNA methylation signatures of fimbrial epithelial cells and ovarian 
surface epithelium cells are partially retained in tumor samples and stratify 
HGSOC samples according to the putative cell of origin of this tumor. 
Moreover, I show for the first time a description of histone modifications in 
primary HGSOC, concentrating on marks of activation/repression sitting on 
promoter regions (H3K4me3 and H3K27me3, respectively) and marks that 
characterize active/closed-poised enhancers (H3K4me1, H3K27ac and 
H3K27me3). 
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5. INTRODUCTION 
 
5.1 Ovarian Cancer 
 
Ovarian cancer (OC) is the fifth cause of cancer-related death for women, and 
the most lethal malignancy among the gynecological ones (Bowtell 2010). This 
disease is usually diagnosed at a late stage, being mostly asymptomatic or with 
vague symptoms that can be attributed to other gastrointestinal or reproductive 
system diseases.  
The standard treatment is mainly based on extensive surgery and treatment with 
cis-platin (or carboplatin), that was introduced in the clinical practice in the late 
70s, more recently in combination with taxanes. Since then, no major advances 
in care of these patients were obtained, made exception of reduced side-effects.  
Indeed, the percentage of 5-years disease-free survival of patients treated with 
surgery and chemotherapy is still below 40% (Vaughan et al. 2011) (Figure 1). 
A subset of OC carrying BRCA1/2 mutations, accounting for less than 10% of 
all OC, is eligible for treatment with poly(ADP)ribose (PARP) inhibitors 
(Bryant et al 2005, Audeh et al. 2010). 
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Figure 1. Current treatments of Ovarian Cancer have not ameliorated patient’s care. 
	
Left panel: the timeline of ovarian cancer treatments since 1960s to date. Right panel: 
disease-free survival curves showing no major improvements since 1980s (adapted from 
Vaughan et al. 2011). 
 
The term “Ovarian Cancer” refers to a heterogeneous group of neoplasms 
rather than a single type of tumor. OC might arise from three different cell 
types: i) epithelial cells; ii) sex cord/stromal cells; iii) germ cells. About 40% 
of all tumors belonging to this group are originally non-epithelial, and usually 
do not progress to the malignant stage, accounting in the end for only about 
10% of ovarian tumors (Karst and Drapkin 2010). Indeed, 90% of these tumors 
arise from epithelial cells (Epithelial Ovarian Cancer, EOC), constituting the 
most predominant form of the disease. EOC per se is a very heterogeneous 
group of tumors that can be classified into eight different subtypes, according 
to the World Health Organization: serous, endometrioid, mucinous, clear cell, 
transitional cell, squamous cell, mixed epithelial, and undifferentiated 
(Tavassoli and Devilee 2003). Within each subtype, tumors are further 
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described as either benign, malignant, or borderline (low malignant potential 
tumors, LMP) and, depending upon tumor subtype, classified as low- or high-
grade.  
Upon diagnosis of malignancy, ovarian tumors are surgically staged, according 
to the International Federation of Gynecology and Obstetrics (FIGO), to 
determine how far they have extended beyond the ovary. Stage I tumors are 
confined to the ovary or fallopian tubes. Stage II tumors extend from ovaries 
and/or fallopian tube to adjacent pelvic structures. Stage III tumors are 
characterized by metastasis to the peritoneum and/or to regional lymph nodes. 
Stage IV tumors metastasize to distant sites (Prat et al. 2015). 
Serous ovarian cancer (SOC) is the most common form of this tumor and is 
classified based on histolopathology and mutational patterns into Type I and 
Type II tumors (Vang et al. 2009). 
Type I SOC evolve by slow transformation of LMP. It comprises low grade 
serous tumors and serous borderline tumors and is characterized by frequent 
mutations in BRAF and KRAS (Singer et al 2003) and devoid of TP53 
mutations (Wong et al 2010). 
An opposed behaviour can be found in Type II SOC that comprises mainly high 
grade serous ovarian cancer (HGSOC). Indeed, TP53 mutations are almost 
ubiquitous (Ahmed et al 2010) while BRAF and KRAS mutations are usually 
not present (Wong et al 2010). Moreover, mutations in DNA repair-genes 
BRCA1 and BRCA2 have been reported (Geisler et al 2002, Hilton et al 2002), 
conferring to this type of tumors high chromosomal instability and hence more 
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sensitivity to platin- and PARP inhibitors-based treatments (Bowtell et al. 
2010) (Figure 2). 
 
Figure 2. Classification of serous ovarian cancers. 
	
a. Histopathological and mutational features of type I and type II SOC; b. DNA copy number 
plot of typical Type I and Type II SOC (Bowtell et al. 2010). 
 
These symmetrical features underline the unlikelihood that high grade serous 
ovarian cancer are temporal progressions of low grade serous tumors, but rather 
a de novo neoplasm characterized by his own typical genetic and epigenetic 
aberrations. 
 
5.1.1 Ovarian cancer cell of origin 
 
The identification of ovarian cancer cell of origin is still a matter of debate. 
Traditionally, since these tumors are diagnosed when they already have 
invaded most of the abdominal portion of patients, including the ovaries, they 
have been attributed an ovarian origin. Growing evidence is suggesting that 
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HGSOC might be instead derived from epithelial cells of the distal portion of 
the tuba, namely the fimbrial epithelium, that is located in close proximity to 
the ovary (Figure 3).  
 
Figure 3. Anatomy of the female reproductive tract 
Schematic representation of the female reproductive tract showing the close proximity of the 
ovarian surface epithelium (OSE) and the epithelium from the distal portion of the fimbria 
(adapted from Ng and Barker, 2015).  
Studies with matched serous tubal intraephitelial carcinomas (STIC) and 
HGSOC revealed the presence of the same TP53 mutations in matched 
samples, suggesting that these tumors could be clonal evolution of pre-
neoplastic lesions in the fimbria (Kuhn et al. 2012). This “p53 signature”, that 
might be even affecting resident stem cells in the fimbria, unveils a scenario of 
fimbria epithelial/stem cells that acquire TP53 mutations and, given the close 
proximity to the ovarian surface epithelium (OSE), shed from their location and 
get trapped in inclusion cysts in the ovary (Ng and Barker, 2015).  
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Very few examples of pre-neoplastic lesions in the OSE have been reported for 
HGSOC (Roland et al 2003). This can be attributed either to the fimbrial origin 
of this tumor, but also to the more permissive environment that ovary 
constitutes for the growth of tumors, as highlighted by the high frequency of 
ovarian metastases originated from gastrointestinal, breast and lung cancers 
(Young 2007). This latter aspect would reconcile with the fact that usually in 
patients carrying very spread HGSOC, STIC are microscopic in size. Most 
probably, the fimbrial environment is less permissive to invasiveness and 
growth than the ovary. When STIC cells are captured in the ovarian stroma, 
they find a favourable environment for growth and development, with 
mechanisms that are still poorly defined (Parrott et al. 2001, Schauer et al. 
2011). So, tumors arising from OSE, being plunged in an optimal environment 
for growth, might be progressing at such rate that it is hard to capture pre-
neoplastic or early lesions in this site. An additional controversial aspect is 
related to the presence of traits of the Muellerian ducts (from which the 
fallopian tube is derived, but not the ovary) in ovarian cancer, especially in low 
grade and borderline tumors. Also in this case, this is either attributed to cells 
shedding from the fimbrial epithelium and included into the ovary, or to 
metaplasia of the inclusion cysts of the ovary, generated from the OSE, into 
“fimbrial-like” cells, possibly for either a high plasticity of putative resident 
stem cells (Szotek et al 2008, Bowen et al. 2009), or related to the common 
mesodermal origin of these two organs. This might explain the preferential 
Muellerian differentiation of OSE cells during metaplasia and neoplastic 
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transformation (Auersperg 2013). 
Given the supporting evidence of both theories, a more unifying vision can be 
envisaged, identifying in both tissues the plausible origin of a subset of 
HGSOC. The identification of signatures that allow to identify for each 
patient’s tumor the precise cell of origin, might allow for a better design of 
studies aimed at the identification of critical pathways that contribute to ovarian 
cancer pathogenesis. 
5.1.2. Current models for high grade serous ovarian cancer 
 
Despite several cell lines are available to model high grade serous EOC, these 
are poorly characterized in terms of histopathological features and site of origin 
(Vaughan et al. 2010). As recently shown in a comparative genomic and 
expression study (Domcke et al. 2013), the cell lines that are mostly used in 
laboratories are quite dissimilar to primary HGSOC samples in terms of the 
amount of genetic mutations, copy number alterations and in terms of gene 
expression patterns (Figure 4).  
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Figure 4. Most commonly used cell lines do not recapitulate HGSOC phenotypes. 
Top left panel: number of publications employing the depicted cells lines. Bottom left panel: 
principal component analysis showing the unrelatedness of ovarian cancer cell lines with 
primary tumor samples at the level of gene expression. Right panels: fraction of altered 
genome (top) and number of mutations per million bases (bottom) of cancer cell lines and 
primary HGSOC (from Domcke et al. 2013). 
 
While this analysis suggests that some undervalued cell lines might be instead 
more useful to model this tumor subtype, highlighting on the contrary that the 
most frequently used ones may prove useless to model HGSOC, such as in the 
case of SKOV3 cells being more closely related to endometrioid cancers, there 
is a strong consensus that new well characterized cellular models should be 
established. 
Animal models can be useful to reveal new insights on HGSOC.  
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Patient-derived xenografts (PDX) have been extensively used to propagate in 
vivo primary tumor cells, that quickly undergo senescence upon culturing. 
They have proved to be useful models to assess drug response in vivo and to 
recapitulate tumors’ heterogeneity (Scott et al. 2013). The limitation of this 
approach lies in the use of immunocompromised mice, probably lowering the 
impact of tumor microenvironment on tumor growth. Moreover, it has been 
shown that at the first passage transplanted tumors lose markers of human 
stroma and vasculature (Hylander et al. 2013), suggesting that host vascular 
and stromal system sustain the growth of engrafted tumors. This can obviously 
affect studies aimed at targeting tumor microenvironment. 
Genetically modified animals instead have been used to address mainly the the 
problem of the origin of HGSOC. Perets and colleauges used a mouse model 
conditionally deleting Brca, Tp53 and Pten specifically in fallopian tube 
epithelium and not in the ovarian surface epithelium by means of a Pax8-Cre 
(Perets et al. 2013). These mice develop high grade serous ovarian cancer, 
going through STIC, a pre-neoplastic lesion of the fallopian tube. In accordance 
with these results, Kim and colleagues (Kim et al. 2012) showed that specific 
deletion of Pten and Dicer in Anti Muellerian Hormone Receptor 2 (Amhr2) 
expressing cells (general female reproductive tract epithelial cells) causes 
emergence of HGSOC from the fallopian tube only, even after removal of the 
ovaries. The same group, though, showed that an additional gain of function 
mutation of Tp53 (p53R172H) results in emergence of HGSOC both from the 
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fallopian tube and the ovary, even in the presence of a wild-type Dicer, 
suggesting that both organs can be suited to the development of this kind of 
tumor (Kim et al. 2015).  
Additional work from Flesken-Nikitin and colleagues (Flesken-Nikitin et al. 
2013), identified a tumor-prone stem cell niche in the hilum, the junctional area 
between OSE, distal fallopian tube epithelium and mesothelium. This area, 
however, is not present in the human specie (Ng and Barker 2015), suggesting 
that this finding might be relegated to the murine setting.  
These controversial results indicate that genetically modified mice can be 
useful to study peculiar mutations, but fail to recapitulate the whole complexity 
of HGSOC. 
 
5.2 Epigenetic aberrations 
 
5.2.1. DNA methylation 
 
DNA methylation is a covalent modification occurring at cytosines of 5’-CG-
3’ dinucleotides (CpG), that is deposited early during development. 
This mark is deposited and maintained by DNA methyltransferases DNMT1, 
DNMT3A, DNMT3B. In normal conditions, CpG islands, stretches of CpG 
sequences usually associated with promoters, are hypomethylated in the 
context of surrounding methylation, a condition that is usually associated with 
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active gene expression. Further modification of methylcytosine by TET 
enzymes results in the deposition of 5’-hydroxymethylcytosine (5hmC), that 
has been proposed as an initial step toward de-methylation. Despite this, stable 
presence of this mark has been reported in active gene bodies (Branco, Ficz and 
Reik 2012) and seems to have a role in areas of plastic nucleosome remodeling 
during differentiation (Teif et al 2014). 
Aberrant DNA methylation occurs commonly in tumors and is considered to 
be one of the earliest molecular changes in carcinogenesis (Baylin and Jones 
2011, Baylin and Ohm 2006). (Figure 5) 
	
Figure 5. Aberrant DNA methylation in cancer. 
Schematic representation of methylation aberrations in cancer. Frequently, TSS-associated 
CpG islands become hypermethylated in the context of larger hypomethylated domains 
(Reddington, Sproul and Meehan 2010). 
 
Candidate gene and whole-genome studies have identified methylation 
signatures that may serve as biomarkers for HGSOC characterization including 
classification (Barton et al. 2008), progression (Wei et al. 2002) and response 
to therapy (Wei et al. 2006). Hypermethylation of DNA occurs mainly at the 
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promoter level of well known tumor suppressor genes, such as BRCA1 
(Baldwin et al 2000), p16 (Katsaros et al 2004) and MLH1 (Zhang et al 2008), 
while hypomethylation has been shown to be occurring in the promoter of 
oncogenes, such as BORIS (Woloszynska-Read et al 2007), CLDN3 and 
CLDN4 (Honda et al. 2006 and 2007), and in repeated regions of the genome 
such as pericentromeric Sat2 DNA at chromosome 1 (Widschwendter et al. 
2004), associated with poor prognosis. It has been suggested that this 
phenomenon increased susceptibility to genomic instability and re-activation 
of retro-transposons (Esteller 2008). 
 
5.2.2. Histone modifications 
 
DNA is wrapped around globular protein complexes known as histones to form 
the fundamental repeating unit of chromatin, the nucleosome. This is 
constituted by 146 base pairs of DNA packed around a histone octamer, which 
is composed by two copies each of histones H2A, H2B, H3 and H4, with the 
addition of one copy of histone H1 that tops this structure and controls higher 
order chromatin compaction. The degree of compaction governs the 
accessibility of DNA, hence the tight regulation of this property plays a crucial 
role in dictating and propagating distinct patterns of gene expression. The fine 
adjustment of DNA accessibility to transcriptional effectors is achieved by 
post-translational modifications (PTMs) of histone tails that extend out of the 
nucleosome core. Several modifications have been described, including 
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methylation, acetylation, phosphorylation, poly(ADP)-ribosylation and 
ubiquitilation. These modifications can play different roles: i) they can serve as 
docking sites for non-histone proteins, that have conserved domains able to 
recognize such modifications, tailoring the recruitment of proteins to specific 
genomic loci; ii) they can alter the ionic interaction between histones and 
wrapped DNA regulating chromatin compaction and permissiveness to binding 
of transcription factors, such as in the case of histone acetylation; iii) they can 
mediate the establishment, maintenance and heritability of the transcriptional 
landscape, such as in the case of Polycomb and Trithorax group of proteins-
mediated histone modifications (Kouzarides 2007, Orkin and Hochedlinger 
2011, Laugesen and Helin 2014, Steffen and Ringrose 2014). Thus, every cell 
of a given organism is characterized by a particular gene expression pattern 
also as the result of the tight interplay between transcription factors and 
different histone modifications.  
Among the best characterized histone modifications, there is methylation of 
H3K4 and H3K27 that is catalyzed by the Trithorax (TrxG) and Polycomb 
(PcG) groups of proteins, respectively. In particular, trimethylation (me3) of 
these lysines is associated to active (Byrd and Shearn 2003) and repressed 
genes (Kirmizis et al 2004), respectively. These groups of proteins were first 
identified in Drosophila melanogaster as regulators of the spatio-temporal 
expression of Hox genes (Lewis 1978), and their action was found to be 
regulating a plethora of other genes, including transcription factors involved in 
cell fate establishment and maintenance. Their role has been shown to be 
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extensively conserved also in mammals (Bracken, Dietrich et al. 2006). 
Genome-wide distribution of these two epigenetic marks have highlighted four 
fundamental chromatin states determined by their tight interplay (Pan et al 
2007, Zhao et al 2007, Mikkelsen et al 2007): i) a repressed state, characterized 
by the presence of H3K27me3 at the promoter of genes; ii) an active state, 
characterized by H3K4me3 at promoter regions of genes; iii) a bivalent state, 
with concomitant presence of both H3K27me3 and H3K4me3 peaks especially 
at the promoter of developmental related genes, which is permissive for low 
mRNA transcription and eager to activation/repression according to lineage 
specification (Bernstein et al. 2006); iv) a mute state, in which both marks are 
absent, and RNA polymerase II is not bound. 
Alterations of the normal equilibrium between these two marks have been 
associated with many tumors. For example, EZH2, the catalytic subunit of 
Polycomb repressive complex 2 that mediates the deposition of H3K27me3, is 
frequently overexpressed in metastatic prostate (Varambally et al. 2002), breast 
(Kleer et al. 2003, Raaphorst et al. 2003), and bladder cancer (Arisan et al. 
2005), and can promote cancer progression through the silencing of the p14 
and p16 (Ink4A/ARF locus) (Bracken et al. 2007). Lysine Methyltransferases 
(KMT2 or MLL), members of TcG and the key regulator of H3K4 methylation, 
are frequently mutated in a variety of cancers (Kandoth et al. 2013). 
In the case of HGSOC, the role of histone modifications is still unclear. High 
expression of EZH2 was found to be correlated with advanced stage, poor 
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survival (Rao et al. 2010), and cisplatin resistance (Hu et al. 2010). This 
suggests a role of repressive histone marks in sustaining late progression of 
ovarian cancer. An interesting finding showed that bivalently marked genes in 
ovarian cancer can favour malignant progression and confer chemoresistance 
to tumors (Chapman-Rothe et al. 2013). Being bivalent domains characteristic 
of pluripotent stem cells (Pan et al. 2007, Xhao et al. 2007), this might suggest 
the emergence of stem-like properties at advanced stages of this disease. 
 
5.3. Inducing Pluripotency in differentiated cell types 
 
Cell potency is defined as the capability of a defined cell to differentiate into 
other cell types. This attribute is progressively lost in the transition from the 
fertilized egg (zygote) to more committed cell types (pluripotent cells, 
progenitors). Terminally differentiated cells lose the capability to self renew 
and to become a different cell type.  
This model, exemplified by Waddington’s “epigenetic landscape” 
(Waddington CH, The strategy of the genes, 1957), which endows a view of 
differentiation as an irreversible process of progressive specification, was 
challenged during the last 60 years by seminal work of various research groups 
which progressively demonstrated that it is indeed possible to: a) revert more 
differentiated cell states in less differentiated ones; b) transition from one 
differentiated cell state to another. 
In 1950s, seminal work by Briggs and King (Briggs and King 1952) and 
	 29	
Gurdon (Gurdon et al 1958) pioneered the establishment of the technique of 
somatic cell nuclear transfer (SCNT). This technique allows the insertion in an 
enucleated egg of a somatic cell nucleus of choice to generate totipotent cells. 
By this approach they showed that albeit the nucleus was derived from a 
differentiated cell, it was still able to give rise to all cells that constitute an 
entire organism (i.e. it is genetically totipotent). This finding was further 
confirmed by cloning of mammals by the same approach (Wilmut et al 1997, 
Hochedlinger and Jaenisch 2002, Eggan et al. 2004). 
These data suggested that it was indeed possible to erase/rewind the 
transcriptional program of terminally differentiated cells to establish a new 
landscape of expression that was typical of the zygote.  
Further confirmation of this finding came later on since the establishment of 
embryonic stem cells (ESC) cultures from mouse (Evans and Kaufman 1981, 
Martin 1981) and human blastocysts (Thomson et al. 1998). These cells when 
fused to differentiated cells could reactivate the expression of pluripotency 
markers in the somatic nuclei (Tada et al. 2001, Cowan et al. 2005), 
highlighting the existence of factors that could drive the re-expression of genes 
associated with the pluripotent state.  
Also, the finding that lineage-associated transcription factors could drive the 
“transdifferentiation” of cells into other cell types, with paradigmatic examples 
described for MyoD in driving the conversion of fibroblasts into myocytes 
(Davis et al. 1987) and C/EBPα in driving the conversion from lymphocytes to 
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macrophages (Xie et al. 2004, Laiosa et al. 2006), pointed to the reversibility 
of lineage determination. 
 
5.3.1. Transcription-factor mediated reprogramming 
 
In 2006 Takahashi and Yamanaka (Takahashi and Yamanaka 2006) proved that 
mouse embryonic and adult tail tip fibroblasts could be reprogrammed to the 
pluripotent state by ectopic expression of four transcription factors (namely 
Oct3/4, Sox2, Klf4 and c-Myc). By screening 21 factors in several 
combinations, infecting MEFs or tail-tip fibroblasts from a Fbx15βgeo/βgeo mice, 
with retroviruses (RV) encoding for these transcription factors, these cells 
could be converted to an ESC-like state and propagated in ESC culture 
conditions. Induced Pluripotent Stem Cells (iPSC) expressed pluripotency-
related genes and could be differentiated into all three germ layers both in vitro 
and in vivo. Even if these cells could not result in viable chimeras upon 
injection into blastocysts and showed differences with blastocysts-derived 
ESC, findings that were later attributed to the choice of Fbx15 as pluripotency 
surrogate instead of a more strictly pluripotency associated gene, such as Nanog 
(Okita et al. 2007), it was the first demonstration that transcription factors can 
drive the conversion to the pluripotent state in differentiated cells.  
In addition to this, this method for the first time allowed to overcome the 
limitations related to other techniques aimed at the induction of pluripotency. 
Indeed, in the case of SCNT, both the technical difficulty of this technique and 
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the low efficiency related to the number of “premium-quality” oocytes to be 
used represent great hurdles for the large scale application of this technique. At 
the same time, generation of human ESC from blastocysts undergoes several 
implications from the bioethical point of view, and cannot always be used. 
The advent of transcription factor-mediated reprogramming, that can be easily 
achieved by expressing a limited number of transcription factors in target cells, 
truly scaled up the possibility to derive pluripotent stem cells for disease-
modeling, in vitro studies and future application for regenerative medicine. 
Since 2006 this approach has been translated to different species including 
humans (Takahashi et al. 2007, Yu et al. 2007, Park et al. 2008) and rhesus 
monkeys (Liu et al 2008), and to different target cells, such as neural 
stem/progenitor cells (Kim et al. 2008, Eminli et al. 2008), melanocytes (Utikal 
et al. 2009), mature lymphocytes (Hanna et al. 2008), adipocytes (Qu et al. 
2012) and many others, showing that this process is universal and can be easily 
translated to the cell type of interest. 
 
5.3.2. Optimization of the reprogramming procedure  
 
Albeit it is possible to translate transcription factor-mediated reprogramming 
to a number of different cell types and species, the efficiency of this process for 
human cells is very low (≤0.01%). Since 2006, many efforts have been made 
in order to optimize the procedure. 
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5.3.1.1. Integration-based systems 
 
The original protocol described by Yamanaka and colleagues was based on the 
retroviral delivery of the reprogramming factors. This procedure is affected by 
the following drawbacks: a) a suboptimal efficiency of delivery, which affects 
the efficiency of reprogramming (only cycling cells will be stably infected 
(Lewis and Emerman 1994), only a fraction of the cells will be infected by all 
vectors); b) multiple integrations in the genome of the cells, which might affect 
genome stability; c) an integration bias towards transcription start sites that 
might result in insertional mutagenesis (Mitchell et al 2004); d) a position-
effect with variegated levels of expression (Yee and Zaia 2001); e) a stochastic 
silencing of the expression cassette due to the presence of CpG islands in the 
RV sequence, which can be transient or stable, influencing the differentiation 
outcome (Yee et al. 2001, Ramos-Mejia et al. 2012).  
In order to reduce the number of integrations and obtain the stable co-
expression of the four Yamanaka factors, mono-/bi-cistronic lentiviral vectors 
have been derived (Carey et al 2009, Sommer et al. 2009). In particular, the 
STEM-Cell Cassette (STEMCCA) described by Mostoslavsky’s group, makes 
use of 2A self-cleaving peptides, that allow cleavage of a single fusion peptide 
to give rise to independent proteins (Donnelly et al 2001), and of an internal 
ribosome entry site (IRES) that allows translation from two separated cistrons, 
under the transcriptional control of a reverse tetracycline transactivator (rtTA); 
this favors sustained expression upon doxycycline administration. In this case, 
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a single copy of the vector was sufficient in order to drive reprogramming of 
MEFs, reducing the potential effects of insertional mutagenesis. Moreover, by 
removal of doxycycline, the vector is silent, reducing deleterious effects on 
differentiation. 
An evolution of this cassette was described in 2010, when the STEMCCA 
vector was modified in order to be expressed from the Elongation Factor 1 
alpha (EF1α) constitutive promoter and to carry LoxP sites in the LTRs in order 
to allow for excision of the single copy integrated provirus upon Cre 
recombinase administration (Somers et al 2010). In this case, vector-free iPSC 
can be generated, even though a single LoxP site is left in the genome as a result 
of Cre-mediated recombination.  
The compromise between the generation of footprint-free iPSC and stable 
expression was reached by the use of PiggyBac transposons (Woltjen et al. 
2009). This system makes use of transposases that insert/excise the Inverted 
Terminal Repeat (ITR)-flanked cassette in a “cut and paste” fashion, without 
altering the locus where the integration has occurred. 
Still, this reprogramming/excision method requires long and tedious screenings 
for excised clones to be used for downstream application. In addition, the 
presence of multiple copies of the genome of repeat-flanked cassettes can cause 
intra/inter-chromosomal rearrangements upon recombinase delivery. 
Moreover, the transient-delivery of the excising enzyme (usually by plasmid 
transfection) requires a quick selection method for transfected cells, and might 
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occasionally result in the random integration of the plasmid by non-
homologous end joining (NHEJ). 
 
5.3.1.2. Non-integrative methods 
 
In order to avoid integration tout-court during reprogramming many different 
approaches have been developed. 
In 2008, Hochedlinger’s lab showed that it was possible to reprogram mouse 
fibroblasts to pluripotent cells without vector integration using adenoviral 
vectors encoding the four Yamanaka factors, albeit with three fold magnitude 
lower efficiency (0.0001% compared to 0.1% with retroviral vectors)(Stadtfeld 
et al 2008). Since the transgenes were delivered as separated vectors and get 
rapidly diluted in cycling cells, this may account for such low efficiency. 
The latter inconvenient was encountered also when transfecting monocistronic 
plasmids (Okita et al. 2008) or nonviral minicircle vectors (Jia et al. 2010) 
Another approach relied on the use of Epstein Barr-derived episomal vectors 
(Yu et al. 2009). In this case seven factors in three individual plasmids were 
used (the four Yamanaka factors plus Lin28, Nanog and the SV40 Large T 
antigen) to reprogram human fibroblasts, even if at very low efficiency. Even 
though it is possible to isolate clones which diluted the episomes, these account 
for one third of all clones and screening is still required to isolate factors-free 
iPSC. Moreover, the immunogenicity of EBNA1 protein (Münz et al. 2000), 
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required for the replication of these constructs, might hamper the application 
of this approach to the regenerative medicine setting, weren’t it be eliminated 
from the cells. 
The very low efficiencies of these approaches based on DNA-based delivery 
were surpassed when Rossi’s group published an innovative approach based on 
the transfection of synthetic modified mRNAs encoding for the four Yamanaka 
factors plus LIN28 (Warren et al. 2010). The 5-methylcytidine and 
pseudouridine modifications, in combination with the supplemented B18R 
protein, by suppressing most of the cellular interferonic response against 
exogenous RNA, increased the stability of the mRNA in the cell and cell 
survival. By daily transfections they obtained vector-free human iPSC with 
efficiencies up to 1.5% in less than 3 weeks. Similar results were obtained by 
the expression of microRNAs belonging to the 302/367 cluster from lentiviral 
vectors (Anokye-Danso et al. 2011), or of miR-200c together with miR-302 
and -369 family by multiple transfections (Miyoshi et al. 2011). 
Despite being the most efficient methods to date, they require daily 
transfections of mRNA/microRNA in order to achieve sufficient expression of 
the transcription factors to drive reprogramming.  
A more recent approach relied on a single transfection of a self-replicative RNA 
derived from the Venezuelan Encephalitis Equine Virus RNA replicon 
(Yoshioka et al. 2013). In this case, efficiencies were variable (~0.01% with 
human adult fibroblasts and up to 1.9% in human newborn foreskin fibroblasts) 
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but in most cases the self-replicative construct could not be detected in iPSC. 
 
5.3.2. Reprogramming of cancer cells to the pluripotent state 
 
Given the strict interplay between genetic and epigenetic aberrations in cancer, 
there is a strong need for an approach that would be able to dissect epigenetic 
from genetic contribution to cancer pathogenesis. Moreover, current models 
lack a complete recapitulation of cancer phenotype. In particular, established 
cell lines and tumor xenograft models provide a much higher fit with advanced 
tumor status. More information on the early stages of tumor development can 
be provided by engineered mouse models. These systems, on the other hand, 
can only provide information on a limited amount of predefined effectors at the 
same time, lacking to recapitulate the intra-patient heterogeneity of primary 
tumor samples. As an additional level of complexity, primary samples cannot 
be propagated indefinitely in culture, so multilayered analysis on fresh samples 
is still a demanding issue.  
iPSC could be a powerful tool to overcome these hurdles.  
The reprogramming process entails a multistep epigenetic resetting (Papp and 
Plath 2013), that allows the establishment of a transcriptional landscape 
compatible with pluripotency. This process could be exploited to reset tumor-
associated epigenetic marks, without disturbing the underlying genetic lesions. 
Cancer-derived iPSC (c-iPSC) would indefinitely expandable and could be 
differentiated in cells derived from all three germ layers. Since a plethora of 
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differentiation protocols towards cancer-relevant lineages is already available 
(Cheng et al. 2012, Ye et al. 2013, Sampaziotis et al. 2015), by the same 
approach it would be possible to study the contribution of genetic lesions to 
early stages of cancer development in different tumor settings. Moreover, the 
well-known phenomenon of “epigenetic memory” of the parental tissue, in this 
setting could become an opportunity to study the effects of retained tumor-
associated epigenetic marks on early tumor pathogenesis (Figure 6) 
	
Figure 6. iPSC-based tumor modeling. 
Schematic representation of cancer modeling through iPSC (adapted from Kim and Zaret 
2015). 
 
5.3.2.1. Evidence for c-iPSC as tools to model cancer pathogenesis 
 
Seminal work by Jaenisch’s lab in 2004 proved the feasibility of 
reprogramming tumor cells into pluripotent stem cells. By converting 
embryonal carcinoma cells (Blelloch et al 2004), and well-characterized mouse 
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cancer cell lines (Hochedlinger et al. 2004), the authors could show that: 
- the pluripotent state can suppress temporarily the tumor phenotype, 
resulting in normal development of the blastocyst. The subsequent 
establishment of tumor-derived ES cell lines was tumor type-dependent; 
- not all tumors could be reprogrammed and give rise to chimeras (only RAS-
inducible, Ink4A-Arf-/- melanoma cells could give rise to ES cells and 
contribute to most tissues during differentiation); 
- reprogrammed melanoma cells could contribute to development up to E9.5 
in tetraploid complementation assays, thereafter the effect of mutations 
disrupted the normal development of the embryo; 
- generated melanoma-iPSC chimeras were tumor prone and developed 
melanomas and rhabdomyosarcomas, that have overlapping pathways. 
In contrast with more recent findings on the antagonistic role of WT p53 during 
reprogramming (Zhao et al 2008, Hong et al. 2009, Li et al. 2009), p53-mutated 
breast cancer cell lines did not give rise to ES lines. This can be attributed to 
the high degree of aneuploidy of the cell line (Kuperwasser et al. 2000). 
Since primary cancer cells and some cancer cell lines could not be 
reprogrammed, many questions were still left open: it was unclear whether 
different mutations could affect the reprogramming procedure, or whether 
different cancer types could not be induced to the pluripotent state. In addition 
to this, still there was no demonstration of human tumors being reprogrammed. 
With the advent of iPSC, overcoming ethical issues on the use of oocytes and 
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technical complexity, it was possible to partially answer to these questions. 
Carette and colleagues (Carette et al. 2010), showed that, upon reprogramming 
of human blast crisis chronic myelogenous leukemia (CML) dependent on the 
expression of the BCR-ABL fusion oncogene, these cells became resistant to 
treatment with imatinib, an allosteric inhibitor of BCR-ABL, despite the 
expression of the fusion protein. This resistance is lost upon differentiation of 
iPSC into hematopoietic lineages only, suggesting that cell lineage-associated 
expression can modulate the activity of oncogenes. Further characterization of 
this model (Kumano et al. 2012) showed that despite imatinib was active in 
these cells, as assessed by the reduced phosphorylation of STAT5 and CRKL 
down-regulation, still iPSC could compensate for this effect and survive the 
treatment. The same resistance occurs in more immature hematopoietic 
lineages but not in differentiated ones, a trait that the authors link to 
subpopulations of putative leukemic stem cells, responsible for treatment 
resistance in patients. 
Miyoshi and colleagues applied the same approach to gastrointestinal tumor 
cell lines (Miyoshi et al., 2010), showing that upon reprogramming and 
differentiation, the tumorigenicity was abolished, an effect that the authors 
attributed to the re-activation of tumor suppressor genes, such as P16, and to 
changes in the transcriptional landscape during the process. These features can 
be attributed also to the differentiation process that was not directed towards 
specific progenitors of the gastrointestinal tract. This results in a 
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methylation/expression profile that is a mean of all cell types present in the 
bulk population of differentiating cells. Also, tumorigenicity in vivo could be 
hampered by differentiation in cell types that are non-permissive to tumor 
transformation in the genetic context of those cancer cells.  
This last hypothesis was confirmed by more recent work in the context of 
glioblastoma cells (GBM) (Stricker et al. 2013). In 2 out of 14 human GBM 
samples, they could establish stable iPSC lines by using piggybac transposable 
vectors expressing OCT4 and KLF4, since SOX2 and MYC were already 
expressed. These iPSC showed loss of methylation upon reprogramming of 
tumor suppressors CDKN1C and TES. By differentiating iPSC into NS cells 
and transplanting the latter in vivo, they could not observe any obvious 
difference from the parental GBM in terms of tumorigenicity, despite the 
reversal of the de/methylation only of a minority of sites. Instead, when 
differentiating these cells towards the mesodermal lineage, specifically into 
chondrocytes, the transplantation of these cells in vivo showed suppression of 
the tumorigenicity, with scoring only of benign masses, if any. Thus, despite 
the presence of mutations that are known to be causal to GBM and other 
tumors, the tumorigenicity of the reprogrammed cells can only be revealed in 
a lineage-dependent manner. 
The last piece of information to date that we can derive from reprogramming 
of cancer cells was provided by Zaret’s group by reprogramming pancreatic 
cells to iPSC-like cells (Kim et al. 2013). Kim and colleagues, showed that 
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differentiation by teratoma formation assay of iPSC-like cells derived from 
pancreatic ductal adenocarcinoma (PDAC), resulted in the recapitulation of 
early lesions of this disease. Indeed, areas of the teratoma developed into early 
stage tumoral lesions, namely pancreatic intraepithelial neoplasia (PanIN). By 
harvesting teratoma lesions at later time points after transplantation resulted in 
the scoring of PDAC lesions, which had evolved from PanIN. Despite being 
tested with the only iPSC line carrying the original lesions of the tumor, named 
“iPSC-like” being dependent on the continuous expression of the exogenous 
reprogramming transgenes, this is the first demonstration that reprogramming 
tumors to a more undifferentiated state allows to study the evolution of primary 
tumor samples through differentiation. 
Despite these seminal experiments that underlined the power of this approach, 
many questions are still left open. To date, cancer-derived iPSC have been 
characterized at the chromosomal level for genetic retention of tumor-
associated mutations. Despite being a proof that these cells are truly derived 
from tumor cells and not from normal tumor-infiltrating cells, still this 
characterization was bound to known mutations already described in the 
literature or at its best to CNV detected through CGH arrays. Single nucleotide 
characterization of tumors and iPSC could give information on the genetic 
composition of tumor subclones. Moreover, since the reprogramming process 
has been shown to induce mutations and chromosomal rearrangements in a 
fraction of cases (Mayshar et al. 2010, Taapken et al. 2011, Pasi et al. 2011), 
this phenomenon should be controlled in order to exclude effects of newly 
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acquired mutations. 
To this regard, the best reprogramming procedure would be endowed with the 
following characteristics: 
- low or no impact on the genome and transcription of the cells: ideally 
integration-free or excisable integrating systems would be the best choice; 
- oncogene-free: methods which allow to avoid the use of c-MYC and/or 
KLF4 would be preferable. 
 
5.3.2.2. Genetic engineering of cancer-derived pluripotent cells 
	
Undirected differentiation of pluripotent cells might not provide the best setting 
for the scoring of the tumorigenic outcome of reset cancer cells. 
Teratoma formation assays are quick and easy to perform but require in depth 
analysis of the whole teratoma to score the phenotype of interest. Moreover, 
the effect of mutations on different lineages cannot be excluded. 
In vitro differentiation of embryoid bodies can be considered an alternative, but 
methods for solid enrichment in developmental precursors of interest must be 
existing or be set up. Indeed, the presence of contaminant cells could hamper 
the molecular characterization of the differentiating progeny. 
To this regard, in the absence of surface markers that could allow specific 
isolation of cells of interest by antibody-based technologies, gene editing could 
be useful to engineer iPSC to carry efficient selection cassettes.
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The groundbreaking discovery of CRISPR/Cas9-based genome editing (Mali 
et al. 2013, Cong et al. 2013), building on previous approaches based on 
meganucleases (Smith et al 2006) zinc finger nucleases (Bibikova et al 2001, 
Hochemeyer et al 2009), TAL nucleases (Miller et al. 2011, Hochemeyer et al. 
2011), allows seamless experimental design and targeted modification in 
pluripotent cells (Mali et al. 2013, Hou et al. 2013). 
This technology takes advantage of an acquired immunity system in 
Streptococcus pyogenes used to recognize and degrade exogenous 
bacteriophage DNA. A guide RNA (crRNA) transcribed from the CRISPR 
(clustered regularly interspaced short palindromic repeats) locus, containing 
pieces of DNA from previous infections, is loaded with a second RNA 
(tracrRNA) within the Cas9 protein and “guided” by homology to the target 
DNA. Here the Cas9 protein delivers a double strand break (DSB) allowing for 
degradation of the exogenous molecule. This process has been exploited by 
combining tracrRNA and custrom crRNA into a single molecule that can be 
expressed from a plasmid and allows site specific delivery of a DSB. This can 
be repaired either by nonhomologous end joining (NHEJ), which is error prone 
and causes insertion or deletion of nucleotides during repair, or by homologous 
recombination in the presence of a donor DNA molecule. This molecule can 
contain a selection cassette flanked by homology regions to the intended site, 
allowing for engineering of virtually any sequence in the genome, as the guide 
RNA is responsible for specificity. 
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By this approach and the appropriate choice of promoters it would be possible 
to target a selection cassette (either with a fluorescent protein or an antibiotic 
resistance or both) that allows selection of the intended differentiating cells. 
Another approach could be used to create isogenic cancer-derived iPSC in 
which the intended mutation is inserted or reverted. The idea would be to verify 
in the same genetic background the role of the gene of interest during tumor 
development. 
 
5.4 Aim of the thesis 
	
The aim of this work is to identify pathogenetic mechanisms underlying 
ovarian cancer, and in particular HGSOC, through the use of two 
complimentary approaches based on induced pluripotent stem cells. The first 
one is aimed at the dissection of the epigenetic vs. genetic contribution to this 
disease through the reprogramming-induced epigenetic resetting of primary 
tumors and differentiation of cancer-derived iPSC into disease-relevant 
lineages. The second one is aimed at the stratification of HGSOC samples, by 
identifying for each tumor its cell of origin, either the fimbrial epithelium or 
the ovarian surface epithelium, through a deeper molecular characterization of 
a unique cohort of primary tumors and normal samples. These two approaches 
would allow the precise identification of disease-relevant pathways, shedding 
light on the molecular mechanisms underlying this disease and leading to 
improved care and therapy of OC-affected patients.	  
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6. MATERIALS AND METHODS 
 
6.1. Tumor biopsy and normal samples dissociation and culturing 
	
Human solid tumors, ascetic cells, fimbrial and ovarian biopsies were provided 
by the IEO biobank.  
Tumor masses were cut into small pieces and resuspended in EDM solution 
(Table 2.1) and kept at 37°C. 
Epithelial cells Digestion Medium (EDM) 
Reagent Volume Final Concentration 
Stock for 1L of medium 
Ham's F12 500 mL  
DMEM 500 mL  
Glutamine 10 mL 1% 
Penicillin/Streptomycin 10 mL 1% 
Insulin 1 mL 1 µg/mL 
Hydrocortisone 2 mL 0.2 µg/mL 
Supplements for 100 mL of medium (to be used by 48 hours) 
EGF 10 µl 10 ng/mL 
Collagenase IA 400 µl 200 U/mL 
Hyaluronidase 1 mL 100 U/mL 
 
Table 1. Epithelial digestion medium composition. 
	
Every 30 minutes cells were resuspended until cell aggregates and single cells 
were released from the tissue. Cells were pelleted at 1500 rpm for 5 minutes 
and resuspended in ACK lysing solution (Lonza) for 2’, in order to lyse red 
cells. Cells were then washed in PBS and centrifuged at 500g for 3 minutes and 
plated on Collagen I coated flasks (BD Biosciences) in EPI medium (Table 1).  
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Epithelial cells culturing medium (EPI) 
Reagent Volume Final Concentration 
Stock for 1L of medium 
Ham's F12 500 mL  
DMEM 430 mL  
FBS (NA) 10 mL 1% 
Glutamine 10 mL 1% 
Penicillin/Streptomycin 10 mL 1% 
Gentamycin 2 mL 0.2% 
Amphotericin 2 mL 0.2% 
Transferrin 10 mL 10 µg/mL 
Insulin 1 mL 1 µg/mL 
Hydrocortisone 10 mL 1 µg/mL 
Hepes pH 7,5 10 mL 10 mM 
Ascorbic Acid 1 mL 50 µM 
Sodium Selenite 25 µl 15 nM 
Etanolamine 6 µl 0.1 mM 
Cholera Toxin 1 mL 50 ng/mL 
Supplements for 50 mL of medium (to be used by 24 hours) 
EGF 5 µl 10 ng/mL 
BPE 165 µl 35 µg/mL 
T3 50 µl 10 nM 
β-Estradiol 50 µl 10 nM 
 
Table 2. Epithelial culturing medium composition. 
	
In the case of ascites fluid, cells were pelleted at 500g for 3 minutes, red blood 
cells were lysed by ACK solution, and derived epithelial cells were plated as 
for solid tumors.  
Fimbriae and Ovaries were incubated in Dispase 1 mg/mL for 30’ at 37°C. 
Epithelial cells from the distal portion of the fimbria and the surface of the 
ovary were then scraped with a scalpel, pelleted at 500g for 3 minutes, red 
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blood cells were lysed by ACK solution, and derived epithelial cells were 
plated as for solid tumors. 
Cells were passaged by trypsin 0.05% and expanded 1:2 or 1:3 according to 
confluency and growth rate of the cells. 
 
6.2. Reprogramming by lentiviral vectors 
	
	
The STEMCCA-OKSM 3rd generation lentiviral vector (LV) was provided by 
Gustavo Mostoslavsky (Somers et al 2010). 
 
6.2.1. Vector production 
	
Vector stocks were prepared by calcium phosphate transfection and 
concentrated by ultracentrifugation. Vectors were produced by transfection of 
human embryonic kidney 293T cell line (containing the mutant gene of SV40 
Large T Antigen), because these cells are optimal DNA recipients in 
transfection procedures and the backbone of the vector constructs contains the 
SV40 origin of replication. 9x106 293T cells were seeded in 15 cm dishes and 
incubated in IMDM 10% FBS, Penicillin and Streptomycin (25U/mL each) for 
24 hours before transfection. One hour before transfection medium was 
replaced. 
To produce LVs, for each dish a plasmid DNA mix was prepared with 9 µg of 
pMD2- VSV-G, 12.5 µg of pCMVΔR9-D64V, 6.25 µg of pCMV-REV, 36 µg 
of STEMCCA transfer construct. 
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The plasmid solution was made up to a final volume of 1125 µL with 0.1X 
TE/dH2O (2:1) in a 15 mL polypropylene tube. Finally, 125 µl of 2.5 M CaCl2 
were added and solution mixed. DNA precipitate was formed by dropwise 
addition of 1300 µl 2X HBS solution (281 mM NaCl, 100mM HEPES, 1.5 mM 
Na2HPO4, pH 7.12, 0.22 µM filtered) to the 1300 µl DNA-TE-CaCl2 mixture 
while vortexing at full speed and immediately added to 293T cells supernatant. 
Cells were incubated at 37°C. for other 14-16 hours after transfection and 
afterward medium was replaced with 16 mL of fresh or 1 mM Na butyrate (for 
donor vectors) containing medium. 30 hours after medium changing, 
supernatant was collected, filtered through 0.22 µm pore nitrocellulose filter 
and ultracentrifuged at 20000 rpm in SW32Ti rotor (Optima L-60 preparative 
Ultracentrifuge; Beckman) for 2 hours at RT. Pellets containing the vector were 
resuspended in a volume of sterile PBS representing 1/500 of the starting 
medium volume, pooled and rotate on a wheel at RT for 1 hour. The 
concentrated vector preparation was then divided into small aliquots (15 µl) 
and stored at -80°C.  
 
6.2.2. Viral transduction of epithelial cells 
 
DAC68, 12-Cit-1, 12_O_313, 12_O_1 and 12_O_333 were subjected to 
reprogramming by the STEMCCA LV. The evening before infection, target 
cells were plated at a density of 7.5x105 cells per well of a six-well plate and 
incubated o/n at 37°C, 5% CO2. The day of infection, 1 mL of freshly prepared 
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EPI medium was applied to cells and 15 µL of 500x concentrated STEMCCA 
virus were added in the presence of Polybrene at a final concentration of 8 
µg/mL. Cells were incubated o/n and the medium was replaced the day after. 
At day 2 post-infection cells were harvested and replated on mytomycin-C 
inactivated MEF-coated 15 cm dishes. The seeding density of MEFs was of 5 
millions of cells per 15 cm dish. At day 5 post-infection EPI medium was 
replaced by hiPSC medium (Table 2), which was daily added to cells until 
iPSC-like colonies appeared. 
hiPSC medium 
Product Cat. Nr. Producer 
Final mix 
(500 ml) 
D-MEM/F-12 (1X) liquid 1:1 21331-046 
Life 
Technologies 
400 mL 
Knockout™ Serum Replacement 10828-028 
Life 
Technologies 
100 mL 
Sodium Pyruvate MEM 100 mM, liquid 11360-039 
Life 
Technologies 
5 mL 
MEM Non Essential Amino Acids 
(100X), liquid 
without L-Glutamine. 
11140-035 
Life 
Technologies 
5 mL 
Penicillin-Streptomycin, liquid 15140-122 
Life 
Technologies 
5 mL 
L-Glutamine 200 mM (100X), liquid 25030-024 
Life 
Technologies 
5 mL 
2-Mercaptoethanol, 50 mM (1000X) 31350-010 
Life 
Technologies 
0,2 mL 
FGF-basic, AA 10-155 Recombinant 
(final concentration 10ng/ml) 
PHG0021 
Life 
Technologies 
0,05 mL 
 
Table 3. Human iPSC medium composition. 
	
6.3. Reprogramming by mRNA/miRNA 
	
Samples 12_O_313 and 12_O_333 were reprogrammed using mRNA/miRNA 
Reprogramming Kit (Stemgent). Briefly, 5x106 million newborn foreskin 
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fibroblast cells (NuFF) (Stemgent) were plated onto a T-75 flask with 25 mL 
of Pluriton medium (Stemgent) and cultured over 8 days. Conditioned medium 
was collected daily and used as reprogramming medium for daily transfections. 
Next, target cells were plated at two different densities (5-7.5x105 per 3.5 cm 
well) onto Matrigel (Corning)-coated plates (diluted 1:40 in DMEM/F12 1:1). 
Medium supplemented with B18R, an inhibitor of IFN-alpha cell response, was 
supplied to cells two hours prior to transfection. Cells were transfected with 
miRNAs on day 1 and 5 and daily since day 2 with the mRNA cocktail (OCT4, 
SOX2, KLF4, c-MYC, LIN28 and SOX2) along with nuclear GFP mRNA 
(Stemgent) for 12 (12_O_333 sample) to 15 days (12_O_313 sample). iPSC-
like colonies were mechanically picked and expanded. 
 
6.4. iPSC culturing 
	
Early passage iPSC were cultured on hESC-qualified Matrigel (Corning) with 
mTESR1 medium (StemCell Technologies) and passaged when at ~70% 
confluency. The passaging procedure required pre-treatment of cells for 2 
minutes with Dispase at 37°C, mechanical picking of undifferentiated cell 
clumps under a microscope and transfer to a new Matrigel-coated plate in 
mTESR1 medium. After 4-5 passages, when the population of iPSC was pure, 
cells were enzymatically passaged. Briefly, medium was removed, cells were 
washed in DPBS 1x and incubated at 37°C with Accutase for 3-4 minutes. Cells 
were single-cell dissociated, harvested in a conical tube with mTESR medium 
and pelleted at 125g for 3 minutes. After removal of the supernatant, cells were 
	 51	
resuspended in mTESR1 medium supplemented with 10µM Rock inhibitor 
(Sigma-Aldrich) and plated onto Matrigel-coated plates. 
 
6.5. Staining of iPSC 
	
	
6.5.1 Immunofluorescence 
	
iPSC were dissociated by Accutase, plated on Matrigel coated coverslips and 
cultured in mTESR1 until the desired dimension of colonies. 
Coverslips were incubated in paraformaldehyde 4% for 20 min on ice, washed 
three times in DPBS, blocked in 10% FBS, 0.1% Triton X-100 in DPBS for 30 
min at room temperature. 
Staining was performed in DPBS supplemented with 10% FBS with the 
following antibodies: anti-OCT3/4 (Santa Cruz, sc-5279, 1:250 dilution) and 
anti-NANOG (Everest Biotech, EB06860, 1:100 dilution). Coverslips were 
stained o/n, washed three times in PBS and the secondary conjugated antibody 
was added in PBS, 10% FBS. After 1 hour of incubation, coverslips were 
washed three times with PBS and mounted with Vectashield mounting medium 
with DAPI (H-1500) on slides. After an o/n, slides were visualized through a 
widefield microscope. 
 
6.5.1. TRA-1-60 live staining 
	
TRA-1-60 Dylight 488 was diluted in fresh medium at 2.5 µg/mL concentration 
and added to live iPSC and left to bind for 30’ at 37°C. Two washes with cell 
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culture medium were performed and cells imaged with an EVOS FL (Thermo 
Fisher). 
 
6.5.2 Alkaline Phosphatase Staining 
	
A solution made of Citrate, Acetone and Formaldehyde was used to fix cells 
for 45 seconds after a wash in DPBS. Cells were rinsed in ddH2O for 30 seconds 
and the staining solution (Sodium Nitrite:FRV alkaline solution 1:1, Sigma) 
was added to cells for 30 minutes. Cells were rinsed in ddH2O and imaged for 
the presence of a red precipitate. 
 
6.6. Teratoma assay 
	
Approximately 4 million iPSC per sample were injected subcutaneously in the 
flank of NOD SCID IL2RGnull mice. Teratomas were taken from the mice, 
washed rapidly in PBS and fixed o/n in 4% formalin solution. The day after 
they were placed in histological cassettes and processed by an automatized 
tissue processor. After processing, the samples were included in paraffin blocks 
and cut with a Leica microtome in 4 µm thick sections that were attached on 
glass slides and stained with haematoxilin and eosin to proceed to the 
identification of cell lineages derived from ectoderm, mesoderm and endoderm 
and the degree of differentiation. 
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6.7. Immunohistochemistry on FFPE sections 
	
The following antibodies were used to stain tumor or teratomas sections: 
Target protein Cat. Nr. Producer Dilution Antigen Retrieval 
S100 Z0311 Dako 1:600 none 
Desmin M0760 Dako 1:20 EDTA 0.25mM pH 8, 30 min 
Pan-CK M0821 Dako 1:400 Proteinase K, 5 min 
NCAM sc-7326 Santa Cruz 1:250 Tris-Sodium Citrate 10mM pH 6, 30 min 
WT1 M3561 Dako 1:200 EDTA 0.25mM pH 8, 30 min 
GFAP Z0334 Dako 1:400 none 
PAX8 10336-1-AP Proteintech 1:500 
Tris-Sodium Citrate 
10mM pH 6, 30 min 
OCT3/4 2750 Cell Signaling 1:200 
Tris-Sodium Citrate 
10mM pH 6, 30 min 
NANOG 4903 Cell Signaling 1:800 
Tris-Sodium Citrate 
10mM pH 6, 30 min 
 
Table 4. List of antibodies used in IHC. 
	
	
Paraffin embedded sections were cut as previously described. Sections were 
washed twice in Bioclear (Bio Optica) for 15 minutes each to remove paraffin 
and hydrated in a descending alcoholic scale with 99%, 95% and 70% ethanol 
(the 99% ethanol step was repeated twice, 5 minutes for each step) and then 
washed in ddH2O. Depending on the antigen different unmasking were 
performed (Table 2.4); endogenous peroxidase was inhibited with 3% 
hydrogen peroxide (H2O2) for 5 minutes. Sections were then incubated in 
blocking buffer (2% BSA in TBST) for 20 minutes; primary antibodies were 
diluted in blocking buffer and incubated for 1 hour at room temperature. After 
washing, sections were incubated with the secondary antibodies for 30 minutes 
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at RT. Counterstaining was performed with hematoxylin (10 s); sections were 
then de-hydrated in 95%, 99% ethanol and Bioclear, 10 minutes each) and 
glasses were mounted using Eukitt (Bio Optica). Signals were revealed using 
Dako EnVision+ Kit. 
 
6.8. Isolation of RNA from cells in culture 
	
12_O_313 and 12_O_333 cells were processed with the RNeasy mini kit 
(Qiagen). Cells were harvested by trypsin 0.05% and pelleted at 500 g in DPBS. 
Dry cell pellets were resuspended in RLT buffer (a highly denaturing buffer 
containing guanidine isothiocyanate) supplemented with 143 mM beta-
mercaptoethanol to inactivate RNases and stored at -80°C until the day of 
extraction. Lysed cells were homogenized by passing through an insulin 
syringe and and ethanol added to the lysate to allow loading onto the 
purification column. A step of digestion of DNA was carried out by the addition 
on column of RNAse-free DNAse (Qiagen). Two rounds of washing eliminated 
all contaminants, while the RNA was eluted in RNase-free water (Qiagen). This 
procedure allows to isolate RNA molecules bigger than 200 nucleotides, so that 
smaller ribosomal RNAs are depleted. 
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6.9. Isolation of gDNA from cells in culture 
	
Cells were harvested by trypsin 0.05% (tumors and normal fimbria and ose) or 
by Accutase (iPSC) and pelleted at 500 g or 125g, respectively, in DPBS. Dry 
cell pellets were stored at -80°C until the day of extraction. 
Using Qiagen DNeasy® blood and tissue kit, cell pellets were lysed in 
proteinase K and RNA was depleted by RNAse (Qiagen). The lysate was 
loaded onto the column. DNA is bound onto the column while contaminants 
passed through. Remaining contaminants and enzyme inhibitors were removed 
by two wash steps, DNA was eluted in ddH2O and stored at 4°C until use. 
 
6.10. Differentiation of iPSC in mesodermal progenitors 
	
6.10.1. Embryoid Bodies 
	
3000 hESCs per well were aggregated by centrifugation to form spin EBs in 
serum-free APEL medium. Cells were treated or not with 50 ng/mL BMP4 and 
20 ng/mL ACTIVIN A (both from R&D Systems) for 6 days, when FACS 
analysis for GFP reactivation was performed. 
 
6.10.1. Adhesion culture 
	
iPSC clone B4 was harvested by Accutase, pelleted in mTESR at 125g for 3’, 
replated in mTESR complemented with 10µM Rock inhibitor on Matrigel-
coated plates at a density of 5x104/cm2. On the following day Stemdiff 
Mesoderm Induction Medium (StemCell Technologies) was applied to cells. 
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At day 4, FACS analysis for the expression of Brachyury T and GFP was 
performed. 
 
6.11. Generation of gene targeting constructs 
	
6.11.1. Donor construct 
	
The donor construct was designed with the Benchling software 
(https://benchling.com) and synthesized by GeneArt (Thermo Fisher). 
 
6.11.2. Guide RNAs constructs 
	
gRNAs were designed on the MIXL1 locus by using the online tool from 
Zhang’s lab (crispr.mit.edu). 
gRNA sense 1: 5’- 
TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGAGCGC
ACGGGACTCGGCTG - 3’ 
gRNA antisense 1: 5’- 
GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACCAGCCG
AGTCCCGTGCGCTC -3’  
gRNA sense 2:  
5’-
TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGGTGCG
CTCCAGTTTGCCGA -3’ 
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gRNA antisense 2: 5’- 
GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTCGGCA
AACTGGAGCGCACC -3’ 
gRNA sense and antisense for each couple were cloned in the gRNA cloning 
vector (Addgene #41824) by the Gibson assembly cloning kit (NEB), 
according to manufacturer’s instructions. 
 
6.11.3. Cas9 and Cas9D10A constructs 
	
Cas9-GFP (#44719) and Cas9D10A-GFP (#44720) were obtained from 
Addgene. 
 
6.12. Gene targeting experiments 
	
6.12.1. Electroporation of iPSC 
	
iPSC were grown in 15 cm-dishes. For the electroporation setup, cells were 
grown up to 70-80% confluency (107 cells approximately), pre-treated with 10 
uM Rock Inhibitor Y-27632 (Sigma-Aldrich, Y0503) for 4 hours, harvested by 
Accutase, resuspended in either ice cold PBS or Gene Pulser Electroporation 
Buffer (Biorad), and transfected with 50 or 100 µg of pCAS_GFP plasmid at 
250V and 500 µF. Cells were then resuspended in mTESR medium 
supplemented with 10 µM Rock Inhibitor and plated on Matrigel coated 15 cm 
plates. Cells were analyzed for GFP-expression 48 hours post transfection. 
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For the gene targeting experiment, PBS was used with the same electroporation 
conditions. The combination of plasmids used in condition A, B, C is depicted 
in Table 5. 
Plasmid Condition A Condition B Condition C 
gRNA 1 25 µg X 12.5 µg 
gRNA 2 X 25 µg 12.5 µg 
Cas9-GFP 25 µg 25 µg X 
Cas9D10A-GFP X X 25 µg 
Donor construct 50 µg 50 µg 50 µg 
 
Table 5. Transfection conditions for the gene targeting experiments. 
	
Cells were then resuspended in mTESR medium supplemented with 10 µM 
Rock Inhibitor and plated on Matrigel coated 15 cm plates. G418 (200µg/mL) 
was used from 48 hours to 15 days after transfection select resistant clones, that 
were picked and expanded for analysis. 
 
6.12.2. Polymerase Chain Reaction (PCR) on the 5’ of the integration 
	
PCR reactions were carried out in a total volume of 25 µL and 200 ng of gDNA 
were used. For the Master Mix, 12.5 µL of Amplitaq Gold 360 Master mix 
(with an hot-start Taq polymerase), 0.5 µM of each primer, and 10% 360 GC-
buffer. GC-enhancer was used as the target amplicon was 63% GC rich. The 
reaction conditions used were the following: 10 minutes of initial denaturation 
at 95°C, 35 cycles consisting of 15 seconds denaturation at 95°C, 30 seconds 
of annealing at 56°C, 3 minutes extension at 72°C, and after the last cycle a 
final 7 minutes extension at 72°C. PCR products were run on 1% agarose gels 
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containing 0.5 µg/mL of ethidium bromide in Tris-Acetate-EDTA (TAE) 
buffer. The expected size of the band was 2739 bp. 
Primer FW: 5’-GGTATCTTTATTGGTGGGCC-3’ (mapping outside the 
homology arm). 
Primer RV: 5’-TATGTTTCAGGTTCAGGGGG-3’ (mapping on the SV40 
poly A). 
 
6.12.4. Digestion of the PCR amplicon 
	
PCR products were purified with the QiaQuick PCR Purification kit (Qiagen). 
Samples were eluted in 21 µL of ddH2O and processed for digestion. 
For digestion 1 µL of BamHI and NaeI restriction enzyme (NEB) were applied 
to the eluted DNA together with 2.5 µL of Cutsmart Buffer. The reaction was 
incubated at 37°C for 4 hours and run on a 3% agarose gel in TAE buffer. 
Staining post-run was performed by incubating the gel with a 0.5 µg/mL 
ethidium bromide/TAE solution for 30 minutes. 
 
6.13. FACS analysis 
	
Tumors, iPSC and differentiating iPSC were harvested as described for 
passaging.  
For surface antigens, FcR blocking reagent was added and cells incubated for 
15’ at 4°C. Directly conjugated antibodies were added according to 
manufacturer’s instructions in 100 µL total volume and allowed to bind for 45’ 
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at 4°C in the dark. Cells were then washed with staining solution at 250 g for 
3’ and resuspended in 100 µL of the same buffer for analysis. 
For intracellular staining, cells were fixed and permeabilized by resuspending 
them in 100 µL of Fix/Perm solution (BD) and incubating for 20 minutes on 
ice. Cells were washed twice with 1x Perm/Wash solution (BD) and incubated 
with the appropriate amount of antibody according to manufacturer’s 
instructions in 100 µL total volume, for 30 minutes on ice in the dark. Cells 
were washed again two times in Perm/Wash solution and resuspended in 200 
µL of the same solution for analysis. 
Cells were run through either the BD FACSCantoII or the BD influx machines 
for acquisition and data were analysed with Flowjo Vx (Treestar). 
Target Fluorochrome Code Supplier Dilution 
CD44 PerCP-Cy5.5 560531 BD Biosciences 1:20 
CD133 APC 293C3 MACS 1:10 
Brachyury T APC IC2085A R&D Systems 1:10 
TRA-1-60 Alexa-Fluor 647 560850 BD Biosciences 1:20 
 
Table 6. List of the antibodies used for FACS analysis. 
	
	
6.14. High-throughput experiments 
	
6.14.1. DNA methylation analysis 
	
gDNA extraction was performed as described in paragraph 2.9. Processing of 
the samples by the Illumina 450k Beadchip kit was performed by our 
collaborator Gilles Gasparoni in Joern Walter’s lab. Briefly, starting from 
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gDNA bisulfite conversion was carried out with the EZ DNA methylation kit 
(Zymo research) according to Illumina’s recommended incubations. Converted 
DNA is subjected to a pre-amplification step, fragmentation of DNA and 
hybridization to a 450K BeadChip, that contains allele specific probes that 
recognize either an uracil (that is generated by the conversion of unmethylated 
cytosines) or a cytosine (when cytosines are methylated they are not converted 
by bisulphite treatment). By single base extension fluorescent nuclotides are 
inserted and signals were imaged with a Hiscan system (Illumina).  
 
6.14.2. Bioinformatic analysis of DNA methylation 
	
Raw data were analyzed by the RnBeads R package (Assenov et al. 2014). 
Briefly, the package performs a quality control of the signals in the chip, 
removes probes with a detection p-value < 0.05 using the Greedycut algorithm, 
normalizes the signal by using the SWAN normalization method, generates 
beta-value of methylation for each probe and summarizes them as being part of 
promoters, entire genes or CpG islands. For unsupervised clustering, I 
considered the top 1000 variable sites, using correlation-based distances for 
hierarchical clustering. For differential methylation analysis, I used the limma 
method and I used the combined ranking to select the top promoters for 
clustering. The combined ranking is generated by the pipeline taking into 
account: i) the difference in mean methylation levels of the two groups being 
compared, b) the quotient in mean methylation and c) the FDR-adjusted p-
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value. For each site the worst of those three rankings (i.e. the highest) is 
established as the combined rank of the comparison. 
 
6.14.3. Whole exome sequencing analysis 
	
gDNAs extracted from tumors, iPSC and blood, were processed by the 
sequencing facility of the IFOM/IEO Campus which performed the following 
part of the protocol; the starting amount of DNA was 10 ng. The overhangs of 
the DNA fragments were converted into phosphorylated blunt ends, using T4 
DNA polymerase, E. coli DNA polymerase I large fragment (Klenow 
polymerase), and T4 polynucleotide kinase. The 3' to 5' exonuclease activity of 
these enzymes removed 3' overhangs and the polymerase activity filled in the 
5' overhangs. A single ‘A’ nucleotide was added to the to the 3' end of the blunt 
phosphorylated DNA fragments, using the polymerase activity of Klenow 
fragment (3' to 5' exo minus). This prepared the DNA fragments for ligation to 
the adapters, which have a single ‘T’ base overhang at their 3' end. Adapters 
were ligated to the ends of the DNA fragments, preparing them to be hybridized 
to a flow cell. DNA was run on a TAE 2% agarose gel to remove excess 
adaptors and selects a size range of templates; a gel slice containing the material 
in the 300±50 bp range was cut from the gel and purified with QIAquick Gel 
Extraction Kit (Qiagen) according to manufacturer instructions. Processed 
DNA was subjected to exon enrichment by the TruSeq exome enrichment kit 
(Illumina) according to manufacturer’s instructions. Briefly, gDNA was 
incubated with capture probes of exonic regions. Then streptavidin beads were 
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used to purify the captured regions and a second round of enrichment was 
performed. Finally, the selected adapter-modified DNA fragments were 
enriched by PCR amplification. The exon-enriched DNA library was diluted to 
16 pM and used for cluster generation and sequencing on an Illumina HiSeq 
machine to obtain 70 million (tumors) or 35 million (iPSC and blood) paired-
end reads, 100 bp length. 
 
6.14.4. Bioinformatic analysis of whole exome sequencing 
	
Quality control of the raw reads was performed using the Fastqc tool 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Each lane of 
sequencing data underwent alignment to the hg19 assembly using BWA 
(Burrows-Wheeler Aligner) algorithm (Li et al. 2009) resulting in sorted 
sequence alignment/mapping file (SAM) format that was converted to binary 
format (BAM) using SAMtools (Li et al. 2009).  
For SNV variant detection, high confidence somatic variant calling was 
performed on the GATK 2.3.4 post-filtered and processed BAM files using two 
callers i) VarScan2 (Koboldt et al. 2012) with its default setting for the reads 
coverage while the p-value threshold set to 0.05 and ii) Mutect (Cibulskis et al. 
2013) with default coverage. Only high confidence somatic variants were 
considered identified by both the methods where no evidence in the matched 
germline sample was included.  
For somatic copy number variation (CNV) analysis, CNV calling was 
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performed with the Control-FREEC tool (Boeva et al. 2011) with window size 
500 and step size 250. Control frequency signals were used as reference to call 
CNV in tumor and iPSC samples. 
For correlation analysis, the correlation heatmap was built based on standard 
deviation and taking in account of the top most dispersed somatic mutations 
(called with GATK) in tumors, iPSC and blood. The top 8000 variants were 
considered with a mutation frequency threshold of 0.4. 
 
6.14.5. Chromatin immunoprecipitation coupled to deep-sequencing 
(ChIP-seq) 
	
Cells were cross-linked with 1% formaldehyde in DPBS for 10 minutes at RT. 
Fixation was stopped by quenching by the addition of 0.125 M glycine for 5 
minutes at RT. Cells were washed two times in DPBS and harvested in SDS 
buffer (100 mM NaCl, 50 mM Tris HCl pH 8.0, 5 mM EDTA pH 8, 0.2% 
NaN3, 0.5% SDS) with protease inhibitors (2µg/mL aprotinin, 5 µg/mL 
leupeptin). This lysate was stored at -80°C until the day of sonication.  
The lysate was thawed in a beaker full of water and centrifuged at 400 g for 6 
minutes. The lysate was resuspended in 130 µl of SDS Buffer:Triton Dilution 
buffer 2:1 (Triton Dilution Buffer: 100 mM Tris-HCl, pH 8.5, 5mM EDTA, pH 
8.0, 0.2% NaN3, 5% Triton X-100), and sonicated by Covaris S220 focused 
ultrasonicator in an AFA 130 µL microcuvette (conditions: 105 peak power, 
5.0 duty factor, 200 cycles/burst, 3 minutes) to obtain a sonicated chromatin in 
the order of ~250 bp. The sonicated chromatin was centrifuged at maximum 
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speed for 30 minutes at 4°C, and the protein content was quantified by Bradford 
assay using BSA (NEB) to derive a standard curve. 2 µL of sonicated chromatin 
were diluted in 800 µL of water plus 200 µL of Biorad Protein Assay and the 
absorbance at 595 nm was measured by a spectrophotometer. 50 to 60 µg were 
used for each IP and diluted in 1 mL of SDS Buffer:Triton Dilution buffer 2:1. 
From this solution, 10 µL were taken to be used as total control (1% input). 
1 µg of primary antibody was added to the chromatin and incubated overnight 
at 4°C on a rotating wheel. ChIP complexes were collected by incubating them 
with 35 µL of protein G dynabeads (Thermo Fisher) (pre-equilibrated with SDS 
Buffer:Triton Dilution buffer 2:1) for two hours at 4°C on a rotating wheel. 
ChIP-bead complexes were put on a Dynamag magnet (Thermo Fisher), the 
supernatant was removed and beads were washed three times with ice-cold 150 
mM Wash Buffer (1% Triton X-100, 0.1% SDS, 150 mM NaCl, 2mM EDTA 
pH 8.0, 20mM Tris-HCl pH 8.0) and one time with ice-cold 500 mM Wash 
Buffer (1% Triton X-100, 0.1% SDS, 500 mM NaCl, 2mM EDTA pH 8.0, 
20mM Tris-HCl pH 8.0). ChIP-bead complexes and the 1% input were 
incubated in 120 µL of 1% SDS, 0.1M NaHCO3 at > 1300 rpm at 65°C 
overnight to reverse crosslink between proteins and DNA. DNA was purified 
with the QiaQuick PCR purification kit (as in paragraph 6.12.4) and eluted in 
43 µL of ddH2O.  
For the sequencing, samples were quantified by Qubit 2.0 fluorometer and 
given to the sequencing facility of the IFOM/IEO Campus which performed 
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the following part of the protocol, as in paragraph 6.14.7.; the starting amount 
of DNA was 10 ng. Diluted libraries were used for cluster generation and 
sequencing on a HiSeq 2000 instrument (Illumina) following manufacturer's 
protocol. ChIPseq was performed in single end, 50 bp with coverage of 30x for 
all the IPs (H3K4me1, H3K4me3, H3K27ac) while the H3K27me3 and inputs 
were sequenced at 60x. 
Histone mark Code Producer Quantity used 
H3K27me3 9733 Cell Signaling 
1 µg/IP 
H3K27ac AB4729 Abcam 
H3K4me1 AB8895 Abcam 
H3K4me3 AB8580 Abcam 
 
Table 7. List of the antibodies used in ChIP experiments. 
	
6.14.6. Bioinformatic analyses for ChIP-seq 
	
The ChIP-seq data quality was checked for quality control with FASTQC tool 
and the alignment of the samples to the hg19 reference genome were made with 
BowTie (Langmead et al. 2009. The peak calling was performed with MACS 
2.0.9 (Zhang et al. 2008) with p-value set as 10-5 and other default parameters. 
The usual peaks output of MACS2 for H3K4me1, H3K4me3 and H3K27ac 
were taken into account while broad peak output files were considered for 
H3K27me3. The annotation for the output peak files was done with the 
HOMER tool (Heinz 2010). 
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6.14.7. RNA sequencing (RNAseq) 
	
RNA Samples were processed with the TruSeq Stranded Total RNA Library 
Prep Kit (Illumina). The starting amount of RNA was 1 µg per sample, as 
quantified by Agilent RNA 600 Nano kit (RNA integrity number: 0.9-1). 
After as step of bead-mediated ribosomal RNA depletion (rRNA removal 
beads, ribo-zero kit), the RNA was also fragmented using divalent cations 
under elevated temperature and primed for cDNA synthesis with random 
hexamers. The primed and cleaved RNA fragments were reverse into first 
strand cDNA using reverse transcriptase and random primers. The RNA 
template was removed and a replacement strand was synthesized with DNA 
Polymerase I to generate double-strand (ds) cDNA. Beads (AMPure XP beads) 
are used to separate the ds cDNA from the second strand reaction mix. 
Overhangs resulting from fragmentation were converted into blunt ends using 
an End Repair Mix: the 3' to 5' exonuclease activity of this mix removes the 3' 
overhangs and the polymerase activity fills in the 5' overhangs. A single ‘A’ 
nucleotide was added to the 3' ends of the blunt fragments to prevent them from 
ligating to one another during the adapter ligation reaction. A corresponding 
single ‘T’ nucleotide on the 3' end of the adapter provided a complementary 
overhang for ligating the adapter to the fragment. This strategy ensures a low 
rate of chimera (concatenated template) formation. Multiple indexing adapters 
were ligated to the ends of the ds cDNA, preparing them for hybridization onto 
a flow cell. PCR was used to selectively enrich those DNA fragments that have 
adapter molecules on both ends and to amplify the amount of DNA in the 
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library. Fragments with only one or no adapters on their ends are by-products 
of inefficiencies in the ligation reaction. Neither species can be used to make 
clusters, as fragments without any adapters cannot hybridize to surface-bound 
primers in the flow cell, and fragments with an adapter on only one end can 
hybridize to surface bound primers but cannot form clusters. The PCR was 
performed with a PCR primer cocktail that anneals to the ends of the adapters. 
The sequencing was performed with an Illumina HiSeq 2000, with paired end 
50 bp reads to achieve a coverage of 35x. 
 
6.14.8. Bioinformatic analysis of RNAseq 
	
The Salmon tool (Zhang et al. 2015) was used to perform transcript-level 
quantification that has a streaming inference method. It is a lightweight based 
algorithm that allows mappings of reads to transcript positions without 
performing a base-to-base alignment of the read to the transcript. The 
transcriptome index was build on hg19. 
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7. RESULTS 
 
7.1 Reprogramming of Ovarian Cancer Cells 
	
Since the discovery of the transcription factor-induced reprogramming, many 
different cell types have been used to generate iPSCs. Anyway, it is still 
unknown whether all cells derived from tumor tissues can be reprogrammed to 
pluripotency and if, among all patient-derived tumors of the same type, all 
mutations can be compatible with the pluripotent state. 
Lentiviral vectors encoding the “Yamanaka factors”, namely OCT4, KLF4, 
SOX2 and c-MYC, have been extensively used to achieve reprogramming. 
Nevertheless, genetic instability is a hallmark of tumor cells and it is therefore 
important to avoid high copy number of integrations that might affect the tumor 
phenotype by insertional mutagenesis. 
To assess whether ovarian cancer cells can be amenable to reprogramming with 
reduced impact on the genome, I made use of the well established human stem 
cell cassette-containing lentiviral vector (STEMCCA LV) (Somers et al. 2010). 
This vector allows reprogramming of fibroblasts from a single copy integrated 
in the genome and expresses all four reprogramming factors from a 
polycistronic vector. Moreover, the presence of LoxP sites in the LTR of the 
LV allows for excision of the reprogramming transgenes by Cre-mediated 
recombination (Figure 7). 
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Figure 7. Schematic representation of the STEMCCA vector. 
LTR: Long Terminal Repeat; EF1α: Elongation Factor 1 Alpha promoter; SD: Splice Donor; 
SA: Splice Acceptor; OCT4: Octamer-binding Transcription factor 4; KLF4: Kruppel-Like 
Factor 4; SOX2: Sex determining region-box 2; Wpre: Woodchuck hepatitis virus Post 
transcriptional Regulatory Element; F2A:	foot-and-mouth disease virus 2A peptide; P2A: 
porcine teschovirus 2A peptide; IRES: Internal Ribosome Entry Site. 
 
I subjected to reprogramming a set of samples comprising normal cells from 
the fimbria, tumor cells derived from ascites, and three primary samples of OC 
characterized by different histopathology (Table 8). Following the protocol 
illustrated in Figure 8a, I was able to successfully reprogram the sample derived 
from the fimbria (DAC68) and the sample derived from ascites (12-Cit-1). 
These cells stained positive for Alkaline Phosphatase (AlkPh) and TRA-1-60 
(Figure 8b), bona fide markers of pluripotency. 
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Figure 8. Generation of iPSC from gynecological samples. 
a. Schematic representation of the reprogramming procedure; b. Representative iPSC 
colonies compared to hESC in terms of morphology (top panels, phase contrast pictures) and 
expression of pluripotency markers such as Alkaline phosphatase (middle panels) and TRA-
1-60 (low panels). 
 
Solid tumors-derived cells were refractory to reprogramming and the overall 
efficiency was very low, with > 30 days necessary to obtain iPSC-like colonies 
(Table 8) 
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Sample Hystopathology # of stable lines 
Overall 
Efficiency 
DAC68 fimbrial epithelium (normal) 5 0.005% 
12-Cit-1 ascites  (from HGSOC) 2 0.002% 
12-O-313 undifferentiated OC 0 0% 
12-O-1 HGSOC 0 0% 
12-O-333 low grade SOC 0 0% 
 
Table 8. Overall efficiency of LV-driven reprogramming. 
	
	
Increasing the multiplicity of infection (MOI) of the vector would increase the 
reprogramming efficiency but would also increase the risk of insertional 
mutagenesis, therefore I decided to switch the reprogramming platform to a 
non-integrative system. Our lab has recently set up a new method based on the 
daily transfection of mRNA and miRNA to reprogram patient’s fibroblasts to 
the pluripotent state (Adamo, Atashpaz, Germain et al., 2015). By this approach 
it is possible to obtain vector-free, feeder-free iPSC in less than 15 days without 
integration of the transgenes. Moreover, contrary to the standard culturing of 
iPSC on feeder cells (usually Mytomicin-C inactivated fibroblasts necessary 
for providing nutrients and growth factors to the cells), this protocol allows the 
direct generation of feeder-free pluripotent cells, avoiding cell type 
contamination in downstream assays (e.g. next generation sequencing). 
I decided to reprogram two samples for which I was not able to obtain any iPSC 
colony despite two months of post-infection culturing, namely 12-O-313 (grade 
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4 undifferentiated OC, hereafter 313) and 12-O-333 (low grade SOC, hereafter 
333). 
By this approach I was able to generate stable iPSC colonies from both tumor 
samples with increased efficiency, and to confirm the expression of defined 
pluripotency markers (Figure 9). 
 
Figure 9. Generation of vector-free iPSC from OC. 
A. Schematic representation of the reprogramming procedure by mRNA/miRNA 
transfection. NUFFs: newborn foreskin fibroblasts; OKSML: OCT4, KLF4, SOX2, c-MYC, 
LIN28. B. Phase contrast pictures of tumor cells (left panels) at the moment of transfection 
and alkaline phosphatase staining (right panels) at the end of the procedure, after picking of 
iPSC-like cells. C. Representative immunofluorescence analysis of OC-derived iPSC. hESC 
and fimbria derived iPSC (DAC68 #4) were used as positive controls. Nuclei were 
counterstained with DAPI.  
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This experiment shows that, at least in this limited set of samples, it is possible 
to reprogram OC cells to iPSCs, albeit with different efficiencies (313 tumor: 
0.01%; 333 tumor: 0.4%). 
To understand whether this difference could be ascribed to the presence of cells 
expressing OCT4 or NANOG already present in the tumor, I performed 
immunohistochemistry staining on the formalin-fixed paraffin-embedded 
(FFPE) samples. These two tumors show low or absent expression of either of 
these factors (Figure 10). 
 
Figure 10. Parental tumors do not show expression of OCT4 and NANOG. 
IHC staining for OCT4 and NANOG in 313 (undifferentiated OC) and 333 (low grade SOC) 
FFPE sections. Haematoxylin is used as counterstaining. Black arrows indicate weakly 
positive cells. 
 
In addition, in order to exclude that the higher efficiency was due to the 
presence of putative cancer stem cells in the starting culture (i.e., prior to 
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reprogramming), I performed FACS analysis for CD44 and CD133, two well 
described markers of putative stem cells in ovarian cancer (Kryczek et al 2012, 
Zhang et al 2008). 
As assessed by FACS analysis, there was no expression of these markers in the 
two samples, proving that the putative stem cell compartment, as defined 
previously, was not responsible for the differences in reprogramming 
efficiency (Figure 11). 
 
 
Figure 11. Parental tumors show comparable expression of putative stem cell markers. 
FACS analysis for the expression of CD44 and CD133 in 313 and 333 tumor cells. Left 
panels: gating for single dissociated cells; Middle panels: selection of living cells based on 
physical parameters. Right panels: Staining for CD44 (y-axis) and CD133 (x-axis). Red dots: 
unstained control; Blue dots: stained sample. 
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Also, by RNAseq I assessed the expression stem cell-related genes were not 
expressed in the original cell culture established for the two samples (Figure 
12) 
 
 
Figure 12. 313 and 333 tumors do not express pluripotency related genes. 
Expression levels of stem cell-related genes in 313 and 333. CD44 and PAX8 were included 
as positive controls (highly expressed genes). 
 
I went on verifying that these cells were reprogrammed to pluripotency at the 
DNA methylation level. I obtained genome wide DNA methylation profiles of 
these two tumor samples and the fimbria together with their respective iPSCs. 
Unsupervised hierarchical clustering based on all normalized methylation 
values shows that, regardless of the parental cells from which they were 
generated, iPSCs cluster away from parental samples, indicating consistent 
DNA methylation re-setting (Figure 13a). By including previously published 
DNA methylation profiles of hESC lines as a reference (Ziller et al., 2011), 
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OC-derived iPSCs cluster together with hESC, as shown both by unsupervised 
clustering of the top 1000 variable sites (Figure 13a) and by overall Pearson 
and Spearman correlation (Figure 13b). Moreover, by looking at POU5F1 and 
NANOG promoter regions, OC-derived iPSCs show consistent de-methylation 
of these regions, with a pattern that closely mirrors that of hESCs (Figure 13c), 
indicating functional reprogramming of these cells. 
 
Figure 13. iPSC are closely similar to human ESC. 
a. Hierarchical clustering of the top 1000 variable sites of hESC, iPSC and parental tissues 
from which they were derived; b. Pearson and Spearman correlation half matrices for the 
samples in a.; c. Methylation profile of POU5F1 (OCT4) and NANOG promoters in parental 
cells, iPSC and hESC. Black dots: CpG with a methylation beta value higher than 0.5; white 
dots: CpG with a methylation beta value lower than 0.5. 
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7.2 Teratoma formation assay 
	
In order to prove the pluripotency of these cells, I subjected iPSCs to in vivo 
teratoma formation assay. By subcutaneous injection of iPSC/ESC, it is 
possible to observe the outgrowth of a benign mass that is composed of 
differentiated cells belonging to ectoderm, mesoderm and endoderm and 
thereby proving that these cells are equivalent to inner cell mass cells. 
In this setting, this approach can be used to evaluate the contribution of somatic 
mutations to tumor transformation. The occurrence of a teratocarcinoma, 
characterized by transformed cells within the mass, would be an indication of 
a major role played by genetic mutations regardless of epigenetic resetting. 
I injected subcutaneously two independent iPSCs clones derived from the 333 
tumor (namely clone #2 and clone #6) into NOD SCID IL2RGnull mice (NSG) 
and isolated teratomas from mice. Strikingly, while clone #6 gave rise to a fully 
differentiated teratoma, without malignant cells throughout the whole mass, 
clone #2 gave rise to both terminally differentiated cells from all three germ 
layers and to malignant areas. Further characterization of this tumor by IHC 
and histological analysis revealed that it was a primitive neuroectodermal 
tumor, a medulloepithelioma, characterized by the expression of cytoplasmic 
WT1, focal GFAP and S100, and NCAM. In addition, the malignant areas 
expressed PAX8, that was not described as a neuroectodermal marker, but that 
was already present in the parental tumor (Figure 14). 
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Figure 14. Differential tumorigenic potential in vivo of 333-derived iPSC. 
IHC analysis of teratomas derived from two independent iPSC clones derived from the 333 
low grade SOC. Left panel: PAX8 staining of the 333 tumor. Middle panels: phase contrast 
pictures of iPSC clones in culture. Top right panels: trilineage differentiation of iPSC, as 
defined by histological analysis (top panels) and marker expression (lower panels). Bottom 
right panels: depiction of neuroectodermal transformation as assessed by histological 
analysis (H&E) and expression of defining markers (lower panels). 
 
7.3. Genetic analysis of OC-iPSC 
	
The different efficiency of reprogramming for these two tumor samples could 
be explained also by the presence of contaminant cells in the culture at the 
moment of reprogramming. Despite the presence of cholera toxin in the 
epithelial culturing medium, that boosts the growth of epithelial cells while 
inhibiting fibroblasts proliferation, the fraction of mesenchymal tumor-
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associated cells can vary from patient to patient. These cells could be 
reprogrammed more easily due to the absence of underlying mutations that 
could hamper the reprogramming process. This occurrence might also reflect 
the different outcome of in vivo differentiation, as clone #2 might be derived 
from a tumoral cell and therefore give rise to malignant areas within the 
teratoma, while clone #6 might be derived from a tumor-associated normal cell. 
To address this point, together with our bioinformaticians, we performed 
Whole Exome Sequencing analysis on parental tumors and two iPSC for each 
tumor. Genomic DNA extracted from the peripheral blood cells of the patients 
was used as a reference. 
 
7.3.1. Single nucleotide variants (SNV) analysis 
	
We used Varscan 2 (Koboldt et al., 2012) in order to call mutations over the 
human genome reference hg19 assembly in our samples. As a first level of 
analysis, we used the frequency of SNVs in each sample to compute a 
correlation value to check if iPSC were more similar to tumors or to normal 
samples. As shown in Figure 3.9, each iPSC showed a higher correlation with 
its respective tumor (Figure 15), indicating that iPSC were more closely related 
to tumor samples.  
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Figure 15. iPSC mutations frequency is more correlated with the one in tumors. 
Correlation analysis of the SNVs frequency in tumors, iPSC and blood. Mutation frequency 
threshold: 0.4. 
 
By filtering out mutations that were present in tumors and iPSC but also in the 
blood samples (germline mutations), we annotated somatic tumor and iPSC 
SNV. We additionally used the MuTect pipeline (Cibulskis et al. 2013) in order 
to derive high confidence mutations, i.e. those identified by both platforms 
pipelines. We defined the overlap between mutations called with each tool, 
highlighting a consistent difference in mutation calling for the two algorithms. 
Therefore, we decided to use only the common mutations to verify the 
reprogramming of tumor cells. 
We intersected the somatic genetic signature of the parental tumors with the 
one derived from matched iPSC and showed that at least a fraction of the 
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mutations found in the tumors were retained in iPSC, suggesting the 
reprogramming of a tumoral subclone rather than a normal tumor-associated 
cell (Figure 16). 
 
Figure 16. iPSC share a fraction of the parental somatic mutations. 
Somatic mutation analysis of parental tumors and their derived iPSC. A. Histogram showing 
the number of mutations called for each sample by VarScan2 (black bars), MuTect (grey 
bars), and common between the two algorithms. B. Overlap analysis of high confidence 
mutations present in tumors and derived iPSC. 
 
7.3.3 Copy number variations (CNVs) analysis 
	
As an additional proof that tumor cells were the ones that underwent the 
reprogramming process, we decided to use the Control-FREEC tool (Boeva et 
al. 2011) on sequencing data, to analyze the content of copy number variations 
(CNVs) in tumors and derived iPSC. Sequencing data coming from peripheral 
bloog gDNA were used as reference to assess gain or losses of genomic content 
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(Figure 17) in the other samples. 
 
Figure 17. Schematic representation of CNVs in tumors and tumor-derived iPSC. 
Sequencing reads from blood-derived genomic DNA were used as a reference. Red signal: 
amplifications of genomic regions; Blue signal: deletions of genomic regions; Green signal: 
non-altered regions. 
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The vast majority of CNVs are represented by amplification of genomic areas, 
with a minor proportion of DNA loss in both tumor samples. By comparing 
tumors and their iPSC we found that roughly 50% of the CNVs detected in 313 
and slightly more than 70% of the CNVs detected in 333 are present in their 
respective iPSC with 100% identity between the parental tumor and its derived 
iPSCs. Moreover, more than half of shared CNVs are common between the two 
iPSC clones derived from the same tumor, suggesting that they are shared 
between different tumor subclones. An estimation of the copy number of CNVs 
reveals that: i) increase in signal is an indication that clonal iPSC are derived 
from tumor subclones; ii) constant intensity of signal indicates that those CNVs 
are common to the vast majority of cells in the tumor (Figure 18). 
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Figure 18. CNVs present in tumors are retained in iPSC. 
A. Proportion of gains (green bars) and losses (purple bars) of genetic sequences in the 
considered samples. B. Percentage of CNVs retained from tumors into iPSC with different 
matching tolerance. C. Overlap analysis of retained CNVs in iPSC that are common between 
the two considered clones for each tumor. D. Predicted copy number of CNVs shared by 
iPSC and their respective tumors in the samples considered. Left panels: 313 background; 
Right panels: 333 background. 
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Taken together, these data indicate, both at the SNVs and CNVs level, that our 
iPSC were derived from tumor cells and not from normal contaminating cells 
in culture.  
 
7.4. Directed differentiation of pluripotent cells into mesodermal 
MIXL1+ cells 
	
In order to study the effect of the epigenetic resetting driven by somatic cell 
reprogramming on tumor cells, I sought to set up a protocol for the 
differentiation of iPSC into mesodermal progenitors, common to both fimbria 
(FI) and ovarian surface epithelium (OSE), the two putative cells of origin of 
ovarian cancer. For the set up I made use of a MIXL1-GFP hESC line, kindly 
provided by Andrew Elefanty’s laboratory. Being the MIXL1 gene expressed 
during primitive mesoderm differentiation, by this approach it is possible to 
isolate early mesodermal progenitor cells to be used for the differentiation in 
vivo of pluripotent cells towards the female reproductive tract epithelium (Ye 
et al. 2011). The protocol relies on the generation of embryoid bodies from ESC 
and their differentiation towards the mesodermal lineage by administration of 
BMP4 and ACTIVIN-A. I subjected the MIXL1-GFP hESC line to 
differentiation and evaluated the expression of GFP by FACS analysis. Up to 
47% of cells scored positive for GFP (Figure 19). 
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Figure 19. In vitro differentiation of the MIXL1-GFP hESC into mesodermal 
progenitors. 
Day 6 post induction embryoid bodies were tested for GFP expression by either FACS 
analysis (left panels) or fluorescence microscopy (right panels). As negative controls for 
FACS analysis, EBs derived from iPSC (GFP negative) were used. APEL: Albumin 
Polyvinylalcohol Essential Lipids medium; BMP-4: Bone Morphogenetic Protein 4. 
 
7.5 CRISPR-Cas9 based gene targeting to track mesodermal 
progenitors 
	
In order to derive a pure population of mesodermal progenitors that could be 
used as a starting point for further differentiation into FI and OSE, I resorted to 
CRISPR-Cas9 technology to target a selection cassette in the MIXL1 locus of 
tumor-derived iPSC. FI and OSE will then be used to define specific gene 
expression and epigenetic signatures characterizing each cell type. 
I designed a cassette that allows: i) G418 selection of clones carrying the 
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integration of the targeting construct, either on- or off-site; ii) selection of 
mesodermal progenitors during differentiation, either by FACS sorting of GFP-
positive cells or by puromycin administration when the construct is integrated 
in frame with the endogenous ATG. FRT sites would allow the excision of the 
PGK-NeoR by administration of the FLP recombinase (Figure 20). 
 
Figure 20. Gene targeting construct and strategy. 
HA: homology arm, 500 bp each; GFP: green fluorescent protein; IRES: internal ribosome 
entry site; PuroR: puromycin resistance gene (puromycin N-acetyl-transferase); FRT: FLP 
recombinase target; PGK: phosphoglycerate kinase promoter; NeoR: neomycin resistance 
gene. 
 
I first set up the optimal electroporation conditions for the targeting constructs 
(pCas9-2A-GFP, the guide RNA expressing plasmid, hereafter gRNA, and the 
donor plasmid) in a normal iPSC line previously generated in our lab (3391B). 
Since the Cas9-expressing plasmid also expresses GFP, it is possible to assess 
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the efficiency of transfection by FACS analysis. (Figure 21) 
 
Figure 21. Setup of the electroporation conditions. 
FACS analysis performed 48 hours after transfection. Top panels: gating strategy. Cells were 
selected on the basis of physical parameters for viability and single cell dissociation, and on 
the basis of TRA-1-60 expression (red – unstained control, blue – stained cells). Middle 
panels: percentage of GFP+ cells (green) in the considered conditions (red – non transfected 
cells). MFI: mean fluorescence intensity. Lower panels: histogram gating for dead/apoptotic 
cells based on the physical parameter FSC (black plot – considered sample, red plot – non 
transfected cells). 
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Transfection in Biorad buffer resulted in high toxicity, even if it increased 
transfection efficiency (higher MFI), therefore I decided to use PBS as 
preferential buffer for electroporation, and a total of 100 µg of plasmid DNA.  
I designed two gRNA to be used in gene targeting experiments, either together 
in combination with the nickase version of Cas9 (Cas9D10A) or singularly with 
the wild type Cas9. Cas9D10A allows the delivery on close genomic regions 
of two single strand breaks that are interpreted by cell’s DNA damage response 
as a double strand break, stimulating DNA repair either by non homologous 
end joining or homologous recombination. Single strand breaks occurring far 
apart in the genome in the case of off-target activity do not stimulate 
homologous recombination, thus reducing potential insertions of the donor 
construct at unintended sites.  
I transfected the appropriate combination of gRNA and Cas9 together with the 
donor plasmid into 3391B cells (condition A: gRNA1 plus Cas9; condition B: 
gRNA2 plus Cas9; condition C: gRNA1 and gRNA2 plus Cas9D10A). 48 
hours after transfection I added G418 to the culturing medium to select clones 
that were transfected with the donor plasmid and subsequently integrated the 
construct. I kept iPSC under G418 selection for three weeks and I picked and 
expanded 11 independent clones from G418-resistant colonies that have 
formed. In order to to assess the correct insertion of the targeting cassette, I 
performed PCR with primers located at the 5’ of the construct, outside the 
homology arms and inside the cassette, I assessed the integration of the cassette 
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on site. Indeed, some of the G418-resistant clones scored positive in all three 
transfection conditions (Figure 22a). I also performed a digestion with BamHI 
and NaeI that cut outside the 5’ homology arm and inside the cassette, 
respectively, showing that the integration was site specific (Figure 22b). 
 
Figure 22. Effective gene targeting at the MIXL1 locus in iPSC. 
A. PCR analysis performed on genomic DNA extracted from G418 resistant clones, specific 
for the 5’ end of the integrated cassette (expected size of the amplicon: 2742 bp). B. 
Digestion of the amplicons belonging to representative clones with BamHI and NaeI 
restriction enzymes (expected size of the digested bands: 2244 bp, 406 bp and 89 bp, black 
arrows). Red arrows: undigested DNA and aspecific cutting. 
 
Moreover, as a proof of principle I differentiated to mesodermal progenitors 
clone B6 showing that GFP+ cells are also Brachyury T+, another defining 
marker of mesodermal differentiation (Figure 23). 
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Figure 23. B6 clone shows reactivation of GFP and expression of Brachyury T upon 
differentiation into mesoderm. 
A. Phase contrast and direct fluorescence image of clone B6 at day 3 post-induction of 
differentiation. B. FACS analysis of the expression of Brachyury T in GFP+ cells at day 3 
post-induction of differentiation. 
 
These results indicate that it is possible to track differentiation into mesoderm 
by gene targeted iPSC in the MIXL1 locus. This approach will be translated 
also to tumor-derived iPSC as an initial step towards the generation of FRTE 
in vivo and for the analysis of molecular phenotypes in vitro. 
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7.6. Molecular characterization of HGSOC and its cell of origin  
	
From DNA methylation analysis of our iPSC and parental cells, I noticed that 
the hierarchy between the parental cells was maintained even after 
reprogramming-induced epigenetic resetting (Figure 12). Indeed, in the 
parental cell group, 333 tumor was closer to the fimbria compared to 313 tumor. 
The same holds true in the iPSC group, where 333-derived iPSC are closer to 
fimbria-derived iPSC compared to 313-derived iPSC. This result suggests that 
despite genome-wide changes in DNA methylation, epigenetic memory of the 
parental cell type is still present. 
I hypothesized that the same phenomenon could occur during tumor 
transformation, so that it could be possible to identify DNA methylation 
signatures reminiscent of those present in the cell of origin in tumor cells. This 
can be especially relevant for OC, where the identification of the cell of origin 
is still controversial. Moreover, in-depth analysis of HGSOC epigenetic 
modifications has been very limited thus far, so there is the need for a better 
understanding of how epigenome can influence transcription and how this 
contribute to tumor pathogenesis. 
Hence, I proceeded with a more detailed molecular characterization of tumor 
cells from HGSOC (EOC), tumor cells isolated from HGSOC patients with 
ascites (AS), fimbrial epithelium cells (FI) and ovarian surface epithelium cells 
(OSE).  
 
	94	
7.6.1. DNA methylation 
	
I subjected to genome wide DNA methylation analysis four fimbria, four OSE, 
four EOC and five AS independent samples, all derived from different patients. 
Aim of the analysis was to determine if DNA methylation was a suitable 
parameter to partition these four categories. 
Indeed, unsupervised clustering based on the top 1000 variable sites across all 
samples showed that these four categories have distinct DNA methylation 
patterns (Figure 24). 
 
Figure 24. DNA Methylation is able to distinguish gynecological tumor and normal 
samples. 
A. Spearman correlation dotplot between the mean methylation values of FI and OSE (top 
panel) and AS and EOC (bottom panel). The transparency corresponds to the dots density. 
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The 1% of the points in the sparsest populated plot regions are drawn explicitly. Red points 
represent differentially methylated sites in the comparison, defined as the top 1000 ranking 
sites. Spearman ρ correlation value is shown. B. Unsupervised hierarchical clustering of the 
top 1000 variable sites across all samples. Colored bars on top define groups: FI (blue), OSE 
(green), EOC (purple), AS (orange). 
	
Differential methylation analysis between FI and OSE samples uncovered a 
methylation signature specific for each category, which I then used to query 
EOC and AS methylomes in order to stratify the samples according to the 
putative cell of origin. 
Interestingly, unsupervised clustering based on the group-specific signatures 
showed that only EOC_003 clustered with FI samples, while all the other tumor 
samples showed closer similarity to OSE (Figure 25). 
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Figure 25. Differentially methylated genes in FI and OSE are able to stratify HGSOC 
samples. 
Unsupervised clustering based on top ranked differentially methylated promoters in FI and 
OSE.  
 
Even if more samples would be needed to strengthen this point, so far we can 
say that specific DNA methylation signatures of fimbrial epithelial cells and 
ovarian surface epithelium cells are partially retained in tumor samples and 
therefore could be used as a tool to stratify HGSOC samples according to the 
putative cell of origin of this tumor. 
 
7.6.2. Chromatin Immunoprecipitation  
	
In the past, cancer was considered to be caused mainly by genetic alterations. 
Nowadays, the view is changed and epigenetic modifications are known to 
influence gene expression, contributing to tumor development. Nevertheless, 
the precise contribution of histone modifications to HGSOC pathogenesis is 
still not well defined. Thus, we performed H3K27me3 and H3K4me3 
promoters profiling and active and closed enhancers characterization by using 
different combinations of H3K4me1, H3K27ac and H3K27me3 modifications. 
In this initial phase we analyzed 3 HGSOC samples (EOC) and 2 tumor 
samples from ascites (AS), that allowed simultaneous analysis of multiple 
marks in cell at the same passage thanks to the abundance of cells derived from 
these samples.  
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7.6.2.1 Promoters 
	
We focused our attention on transcription start sites (TSS), deriving 
localization maps for H3K27me3 and H3K4me3 in a range of 1kb up- and 
down-stream the TSS. As expected, we were able to classify TSS in four classes 
according to histone mark occupancy, namely those marked by i) H3K4me3 
only, ii) H3K27me3 only, iii) both marks (bivalent TSS) or iv) neither marked 
TSS (Figure 26). 
 
Figure 26. HGSOC samples show homogenous TSS marking across samples. 
Heatmap showing the distribution of H3K27me3 and H3K4me3 marks on all TSS in EOC 
and AS. 
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This analysis did not highlight any major difference in the overall distribution 
of the marks between the two groups of samples (EOC and AS). We then 
analyzed more in details TSS belonging to categories i) and ii) as previously 
defined. Interestingly, the overlap of H3K4me3+ TSS across different samples 
of the same kind (EOC or AS) is greater than 80% (86% on average for EOC 
and 89% on average for AS samples). On the contrary, the overlap of 
H3K27me3+ TSS across different samples of the same kind is about 16% on 
average for both EOC and AS samples.  
We then used the results of the overlaps representing the common TSS in EOC 
and in AS (and therefore overcoming the patient-specific distribution of histone 
marks) to compare the two different stages of the tumor (EOC vs AS) (Figure 
27a). The vast majority of H3K4me3+ TSS are shared between EOC and AS, 
while less than 30% of H3K27me3+ TSS bear the mark at both stages (Figure 
27b), suggesting that while the H3K4me3 is less variable at different tumor 
stages, H3K27me3 has more stage-specific localizations.  
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Figure 27. Differential occupancy of H3K27me3 and H3K4me3 histone marks at TSS 
in EOC and AS. 
A. Group-based overlap analysis of H3K4me3- and H3K27me3-marked TSS in EOC and 
AS samples; B. Identification of exclusive and common H3K27me3- and H3K4me3-marked 
TSS in EOC and AS. 
 
H3K27me3+ TSS were too few to perform an enrichment test, and therefore we 
performed ingenuity pathway analysis only on H3K4me3+ TSS in EOC and 
AS. For EOC, the analysis uncovered an enrichment for genes involved in the 
inhibition of matrix metalloproteases, Wnt/beta-Catenin and cAMP signaling. 
For AS, instead, the best ranking pathways are associated to mediators of intra-
cellular response (Figure 28). 
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Figure 28. Ingenuity pathway analysis performed on exclusive H3K4me3-marked 
TSS in EOC and AS. 
	
We reanalyzed with our computational pipeline the dataset produced by 
Chapman-Rothe and colleagues (Chapman-Rothe et al. 2013) on a single 
HGSOC and verified that the gene promoters they selected and validated as 
belonging to H3K27me3 only (EN1 and ZIC4), H3K4me3 only (FBXO33 and 
IKBIP) and bivalent (ALX1 and COCH) groups were still marked with the 
same histone modifications in the re-analyzed dataset. Next, we sought to 
verify whether their findings could still hold true in our dataset. 
Interestingly, we found that while their H3K4me3 marked promoters fell into 
the same group also in our EOC samples, H3K27me3 marked promoters 
switched invariably to the H3K4me3+ category in our dataset and bivalent 
promoters were either confirmed or found in the H3K4me3+ class (Table 9). 
Moreover, the overlap of TSS belonging to each category in our classification 
and in the one presented by Chapman-Rothe and coworkers is overall very low, 
with the greatest overlap in the H3K4me3 only category (around 55%) (Figure 
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29). 
Gene promoter HGSOC (Chapman-Rothe) EOC_319 EOC_05 EOC_23 
EN1 H3K27me3 H3K4me3 H3K4me3 H3K4me3 
ZIC4 H3K27me3 H3K4me3 H3K4me3 H3K4me3 
FBXO33 H3K4me3 H3K4me3 H3K4me3 H3K4me3 
IKBIP H3K4me3 H3K4me3 H3K4me3 Not present 
ALX1 Bivalent Bivalent H3K4me3 H3K4me3 
COCH Bivalent H3K4me3 H3K4me3 Bivalent 
 
Table 9. Categorization of the selected genes in the published sample and in our 
dataset of EOC. 
Green: coherent categorization with our dataset; Red: Incoherent categorization with our 
dataset. 
	
 
Figure 29. HGSOC published dataset shares a minority of peaks with our samples. 
Venn diagrams showing the overlap of marked TSS in the considered groups between our 
samples and the published HGSOC. 
 
These results suggest that the number of samples used greatly influences the 
definition of specific marks at promoter regions in HGSOC. 
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7.6.2.2. Enhancers 
	
In a preliminary analysis, we sought to identify putative enhancers specific for 
the EOC and for the AS samples. We defined enhancers taking into account a 
region spanning 1 to 5kb upstream the TSS, and classified them as active, when 
we found co-localization of H3K4me1 and H3K27ac, or as closed/poised when 
H3K4me1 co-localized with H3K27me3 (Heintz et al. 2015). 
By comparing active or closed enhancers in EOC and AS, we saw that the 
overlap was greater for active enhancers, while closed/poised enhancers were 
less conserved between the two groups (overlap percentages: 51% in EOC and 
65% in AS for active enhancers and 10% in EOC and 36% in AS for poised 
enhancers). As shown by the Venn diagrams, at each tumor stage we found a 
set of specific active and poised/closed enhancers (Figure 30).  
 
Figure 30. Distribution of putative active and closed/poised enhancers in EOC and 
AS. 
Venn diagram showing common and exclusive active and closed/poised enhancers in EOC 
and AS.  
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Both in the case of promoters and enhancers, it will be interesting to compare 
the ChIP-seq data with transcriptomic data. If the active or “repressed” status 
suggested by promoters and enhancer is reflected by gene expression, this 
might represent an interesting molecular finding to shed new light on epigenetic 
contribution to ovarian cancer pathogenesis. 
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8. DISCUSSION 
 
Ovarian Cancer is a leading cause of cancer-related death, with high incidence 
and mortality due to the failure of surgery and chemotherapy to eradicate the 
disease. Currently available cellular and animal models fail to fully recapitulate 
both tumor genetic heterogeneity and histopathology. Also, the uncertainty 
regarding the actual cell of origin of this class of tumors has hampered the 
identification of relevant targets for therapy. Additionally, to date very little is 
known about the epigenetic vs. genetic contribution to this disease, thus 
pointing to a strong need for innovative research that might contribute to the 
elucidation of fundamental mechanisms driving OC pathogenesis. 
The work presented in this thesis made use of two complementary approaches 
based on somatic cell reprogramming to pluripotency to address the following 
issues: i) the functional dissection of the reciprocal contribution of epigenetic 
and genetic contribution to ovarian cancer pathogenesis through 
reprogramming of tumor cells and differentiation into the female reproductive 
tract epithelium, and ii) a fine characterization of HGSOC molecular signatures 
that can be used to identify the cell of origin of this tumor type. 
For the first part, my central hypothesis was that reprogramming to iPSC would 
allow the erasure of tumor-associated epigenetic marks without affecting the 
underlying mutated genome. Then, the in vivo differentiation of OC-derived 
iPSC to female reproductive tract epithelium (FRTE) would unfold the 
epigenetic mechanisms that evolved during the parental tumor progression. In 
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this context, the analysis of differences at the epigenomic and transcriptomic 
level compared to the parental tumor would allow the description of relevant 
pathways for the disease progression. 
Thus far, it is still unknown whether all cancer types can be reprogrammed to 
the pluripotent state, since some genetic lesion might hamper the 
reprogramming process per se or the stability of pluripotency. Moreover, a 
careful choice of the most appropriate reprogramming platform is needed in 
order to: i) minimize the risk for insertional mutagenesis, i.e. insertion of the 
reprogramming vector in a gene body, causing the knockout of the gene, or the 
up-regulation of nearby genes’ expression, due to the interaction with splicing 
sites and transcription factor binding sites that are present in some of the 
promoters used (Lombardo et al. 2011); ii) avoid residual expression of the 
reprogramming transgenes either at the iPSC stage or during differentiation. 
Indeed, the reprogramming cocktail include oncogenes as c-MYC and KLF4, 
whose transient expression has also been demonstrated to drive tumorigenesis 
per se (Ohnishi et al. 2014).  
Keeping in mind these caveats, I made use of the STEMCCA LV (Somers et 
al. 2010), a single LoxP-flanked excisable vector expressing the four 
Yamanaka reprogramming factors, that allows the reprogramming of 
fibroblasts to iPSC from a single integrated copy. This would minimize the risk 
of unwanted inter-/intra-chromosomal recombination upon Cre-recombinase 
administration during the excision of the reprogramming vector, that is done in 
	106	
order to avoid expression of the transgenes during differentiation. 
However, this approach was inefficient to drive reprogramming in most of the 
available samples, with few exceptions that were reprogrammed despite with 
very low efficiency. This could be attributed either to an intrinsic inefficient 
reprogramming of tumor epithelial cells from a single-copy vector or to the 
presence of mutations that could hamper the reprogramming process. 
Thus, I took advantage of recent successful reports describing the use of either 
mRNA or miRNAs related to pluripotency to generate iPSC (Warren et al. 
2010, Anokye-Danso et al. 2011) and I applied an integration-free approach 
based on the daily transfection of a combination of both miRNA and mRNA, 
that our lab had previously described to generate vector-free iPSC from 
fibroblasts in less than 15 days (Adamo, Atashpaz, Germain et al. 2015).  
With this method, I was able to obtain iPSC from two samples (one 
undifferentiated ovarian carcinoma and one low grade serous ovarian cancer) 
that in the first experiment were refractory to viral-based reprogramming 
(Table 8 and Figure 9). These iPSC lines could be expanded for more than 30 
passages, maintaining an undifferentiated phenotype and the expression of 
pluripotency markers. At the DNA methylation level, they closely resemble 
human ESC lines genome-wide, with consistent de-methylation of NANOG 
and OCT4 promoters.  
The two samples were reprogrammed at different efficiencies, with a 
surprisingly higher efficiency in the low grade tumor with respect to the 
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undifferentiated tumor. It has been shown that reprogramming is more 
amenable in cells that are less differentiated, such as in the case of adult and 
fetal neural stem cells (Kim et al. 2008, Kim et al. 2009). Moreover, more 
aggressive HGSOC express pluripotency markers NANOG and OCT4 (Siu et 
al. 2013, Peng et al. 2010). Finally, surface markers CD133 and CD44 have 
been associated with putative cancer stem cells in HGSOC (Kryczek et al. 
2012, Zhang et al. 2008), suggesting that there are subpopulations in higher 
grade OC characterized by a more undifferentiated state and therefore more 
prone to reprogramming. Despite this, I found that most of the aforementioned 
genes were not expressed, with the exception of CD44 that had a comparable 
expression in both samples. The lack of expression of stem-associated markers 
suggests that the difference in reprogramming efficiency cannot be explained 
by the presence or absence of stem-like cells in the tumors. 
I performed whole exome sequencing analysis on tumor samples and their 
derived iPSC to rule out the possibility that the cell culture established from 
low grade tumor contained normal mesenchymal tumor-associated cells. In this 
scenario, if tumor mutations are detrimental to the reprogramming process, 
normal cells could have been reprogrammed instead of tumor cells. Anyway, 
as showed both at the SNV and CNV level, iPSC share a good fraction of the 
parental tumor genetic aberrations. This evidence proves that iPSC are indeed 
derived from tumor cells and not from contaminant cells.  
Moreover, if early-stage mutations, i.e. present in all cells of the tumor, were 
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incompatible with the pluripotent state, we would have failed in obtaining any 
iPSC. The reprogrammed clones therefore carry early stage aberrations that 
occurred early in the parental tumor. 
The differentiation potential of OC-derived iPSC was assessed by teratoma 
formation assay in vivo. OC-derived iPSC were able to differentiate into all 
three germ layers, proving the pluripotency of these cells. Interestingly, one 
clone gave rise to a teratocarcinoma recapitulating the features of a 
medulloepithelioma (Ulbright et al. 2010), a primitive neuroectodermal tumor 
(PNET). The medulloepithelioma unexpectedly expressed PAX8, one of the 
defining markers of serous ovarian cancer (Laury et al. 2011), that was already 
expressed in the parental tumor but that has never been associated with PNET.  
Several explantions can justify this finding. One could be that there were 
mutations in the parental tumors found with very low frequency, possibly due 
to the heterogeneity of the tumor bulk, that we were not able to detect with the 
depth of sequencing we used. A portion of these mutations might be exclusively 
represented in one clone of iPSCs and be causal to specific features of each 
single iPSC clone (e.g., the aberrant expression of PAX8 in the tumor and in 
the teratocarcinoma). More in general, this would support the idea that 
mutations we found to be exclusive to iPSC could be instead present in the 
tumor and not being detected, arguing against de novo acquisition of mutations 
during reprogramming. 
Another hypothesis could be that epigenetic resetting occurred during the 
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reprogramming process was able to suppress the tumor phenotype in some 
clones, while tumor transformation upon differentiation with, as an example, 
persistence of PAX8 expression could be the result of epigenetic memory of 
the parental tumor in other clones.  
Combining transcriptomic data and a more detailed analysis of DNA 
methylation in the parental tumor and iPSC, could help in shedding light on 
this result. 
CNV analyses on tumors and iPSC also provided a snapshot of the tumor 
genetic landscape. Indeed, since iPSC are generated from a single cell in 
culture, they act as a “magnifying lens” on the genetic composition of 
subclones in the heterogeneous tumor bulk. An in depth analysis of mutated 
and gained/lost genes on a greater number of iPSC clones per tumor would 
allow the genetic reconstruction of the subclones present in the parental tumor 
and to deconvolute tumor genetic heterogeneity. Moreover, it will also help in 
tracking the evolution of the tumor: since iPSC are clonal, a consistent increase 
in frequency of genetic alterations from tumor to iPSC would indicate that these 
mutations are less represented in the parental tumor. Unchanged frequencies 
instead would indicate that the mutations are present in the vast majority of 
tumor cells, pointing to early events in tumor pathogenesis. Also, the clonality 
of iPSC would allow to assign defined haplotypes to subclones present in the 
tumor bulk, allowing the reconstruction of the genetic evolution of the 
considered tumor.  
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Next, I sought to set up a streamlined platform for the generation and isolation 
of mesodermal progenitors from iPSC. This would allow to study in vivo the 
progression of differentiating tumor-derived iPSC, and to study the effect of 
epigenetic resetting on the cancer genome, by comparing the parental tumor 
and the differentiating cells both at the histopathological and molecular level. 
Our lab has previously shown that disease-relevant transcriptional phenotypes 
are already detectable at the iPSC stage and are amplified during differentiation 
(Adamo, Atashpaz, Germain et al. 2015). Since tumor-derived iPSC carry 
tumor mutations, it is plausible that during differentiation any effect at the 
molecular level might be present already in mesodermal progenitors, a common 
ancestor of both fimbria and ovarian surface epithelium. Moreover through this 
intermediate step, it would be possible to terminally differentiate iPSC in vivo 
by generating female reproductive tract epithelium (Ye et al. 2011).  
I resorted to CRISPR/Cas9 technology to integrate a GFP-puro cassette in the 
MIXL1 locus, in frame with the endogenous ATG, and managed to isolate iPSC 
clones carrying proper integration that allows selection of a pure population of 
mesodermal progenitor cells during differentiation (Figure 21-22).  
These cells will be used for the identification of stage-type specific epigenetic 
and transcriptional signatures by ChIPseq, DNA methylation and RNAseq 
analyses. 
To this regard, this same approach could be implemented for the 
characterization of HGSOC cell of origin, that thus far is still controversial. 
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Mesodermal progenitors derived from normal iPSC from female donor could 
be used to define fimbria and OSE specific epigenetic and transcriptional 
signatures. One can expect that, despite being the result of genetic and 
epigenetic aberrations, HGSOCs would still retain epigenetic features that are 
characteristic of either Fimbria or OSE. The preliminary analysis based on 
DNA methylation of samples belonging to fimbria, OSE, solid HGSOC and 
ascitic cells showed that it is possible to distinguish all the four categories 
accordng to their DNA methylation profiles (Figure 24). Particularly, I could 
show that HGSOC and ascites more closely correlate with OSE, with the 
exception of one sample that instead showed very high correlation with fimbria 
promoters methylation pattern. As far as we can evaluate from this limited set 
of samples, these data confirm the initial hypothesis that different HGSOC 
samples can derive from both cell types, and DNA methylation could represent 
a good marker for the identification of the cell of origin. In order to strengthen 
this result, more samples will be subjected to the same analysis.  
Distribution of well characterized histone modifications has been examined in 
a cohort of HGSOC and ascitic samples. As a first level of analysis we selected 
histone modifications marking active or repressed promoter regions (H3K4me3 
and H3K27me3, respectively) (Byrd and Shearn 2003, Kirmizis et al 2004) and 
active or closed/poised enhancers (H3K4me1 in combination with either 
H3K27ac or H3K27me3, respectively) (Heinz et al. 2015). TSS were classified 
in four groups according to histone mark occupancy, namely those marked by 
i) H3K4me3 only, ii) H3K27me3 only, iii) both marks (bivalent TSS) or iv) 
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neither marked TSS.  
We focused on the first two classes and showed that the vast majority of 
H3K4me3-marked TSS is conserved across tumor samples, while we could 
score higher inter-sample variability in the case of H3K27me3 TSS. Moreover, 
most H3K4me3-marked TSS were shared in the transition from EOC to AS, 
while H3K27me3-marked TSS were more specific to each category. This 
finding could be attributed to a higher conservation of activation marks, with 
lower consistency of silenced genes in HGSOC and in AS. Another possibility 
could be that the different nature of H3K27me3 deposition at TSS, 
characterized by less sharp peaks and a broader distribution, results in more 
difficult peak calling by current statistical methods. Indeed, we found that the 
number of peaks identified for H3K27me3 was greatly lower with respect to 
H3K4me3. Moreover, depending on the distribution of the peak (i.e. centered 
on the TSS, spread on the promoter with a narrow depletion on the TSS, spread 
on the whole gene body), it has been proposed that this mark can either suppress 
or favour transcription (Young et al. 2011), adding another level of complexity 
to the understanding of its functional role. In addition to this, we are currently 
profiling the transcriptome of these cells. The correlation between the 
distribution of epigentic marks (both histone modifications and DNA 
methylation profiles) and gene expression on a large number of samples could 
consequently clarify how chromatin modifications affect tumor pathogenesis, 
overcoming the inter-patient variability.  
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By comparing our data with the only dataset present in the literature (Chapman-
Rothe et al 2013), we also argued that analyses performed on single or few 
tumor samples could be of limited value for the dissection of HGSOC 
pathogenesis. Increasing the number of samples would be mandatory to 
identify reliable epigenetic features of HGSOC.  
The difficulty in peak calling for H3K27me3 could also be the reason why the 
number of closed/poised putative enhancers we identified was considerably 
lower with respect to active ones. To address this issue, we will perform 
NOMe-seq analysis (Kelly et al. 2012) to evaluate nucleosome occupancy at 
these sites, since more compacted or open chromatin at enhancers has been 
associated with activity or poisedness (Heinz et al. 2015). 
Normal samples and mesodermal progenitors from normal iPSC will be 
included in the study, to finely characterize specific epigenetic features of 
fimbria and OSE that are retained in HGSOC samples, addressing the problem 
of the cell of origin of the tumor. This would allow to refine the identification 
of relevant dysregulated pathways in HGSOC according to the tumor-specific 
relevant cell of origin, hopefully leading to the discovery of clinically relevant 
targets for a better care of OC patients. 
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